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ABSTRACT 
Glycoscience is important in many areas such as human health, energy and material science.  
Glycans have been shown to be involved in the pathophysiology of almost every major disease. 
Additional glycan structure knowledge is required to help advance personal medicine, and 
pharmaceutical developments, among others.  For glycoscience to advance there is a need for 
large quantities of well-defined glycans and have quick access to glycosyltransferases for 
manipulating glycan synthesis.   
Herein, we will cover our efforts on studying the substrate specificities of human 
glycosyltransferases such as FUT8 and Gn-T V, and their application on N-glycan synthesis.  
Complex asymmetric N-glycan isomer structures have been related to many diseases such as 
breast cancer, among others.  Synthesis of complex asymmetric N-glycan isomer structures 
including: a1,6 core-fucosylated, and tri-antennary structures can be achieved by taking 
advantage of the high specificity of glycosyltransferases that can work as unique catalyst to 
generate well-defined glycan structures.   
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1 INTRODUCTION  
1.1 Purpose 
The goal of this dissertation is to study and apply human glycosyltransferases (hGT) 
substrate specificity to N-glycan synthesis.  Five hGT were expressed, purified and their 
activities assayed.  Two of them were used in synthetic schemes for the extension and separation 
of asymmetric N-glycan isomers.  hGTs are enzymes involved in the glycan biosynthesis. The 
natural overexpression of some of these enzymes such as FucT8 and Gn-T V can contribute to 
the development, progression, malignancy, recurrence, invasive and metastatic properties of 
cancer cells, among others. 1-5  
 The following are the hGTs that were expressed: 1. a-1,3-mannosyl-2-b-N-
acetylglucosaminyltransferase (Gn-T I), 2. a-1,6-mannosyl-2-b-N-acetylglucosaminyltransferase 
(Gn-T II), 3. b-1,4-mannosyl-2-b-N-acetylglucosaminyltransferase (Gn-T II), 4. a-(1,6)-
fucosyltransferase (FUT8), and 5. b-1,6-mannosyl-2-b-N acetylglucosaminyltransferase (Gn-T 
V).  The substrate specificity studies on these enzymes have and will continue to be applied 
towards the development of libraries of structurally well-defined N-glycans, which is an urgent 
scientific need for quantification and characterization of N-glycans on proteins, rapid analysis of 
carbohydrate binding proteins (CBPs), and the development of diagnostics and therapeutics for 
many diseases.  This research area is challenging due to the complexity, diversity and low 
abundance of glycan structures. The availability of structurally well-defined N-glycan libraries is 
essential to help solve these issues. However, only a small number of N-glycans are currently 
commercially available, which is a disadvantaged for glycobiology research.  
Our group developed an N-glycan library, which established an efficient chemo-
enzymatic strategy, named Core Synthesis/Enzymatic Extension (CSEE), for rapid production of 
12 
 
diverse N-glycans.6 Taking advantage of this method asymmetric core-fucosylated N-glycans 
(CF-glycans) can be chemo-enzymatically synthesized in order to extend our existing library. 
The generation of well-defined core fucosylated N-glycan structures are useful as standards for 
quantitative glycomics, analysis of glycan structures, and as antigens for the production of 
diagnostic antibodies.7  Taking advantage of well-studied substrate specificity of two out of the 
five hGTs  expressed (FUT8 and Gn-T V) enzymatic separation of asymmetric N-glycan isomers 
was accomplished. Insight on the substrate specificity of these important hGTs is important for 
future development of N-glycan synthesis. 
In the following Chapters this dissertation will cover: Chapter 1 a brief introduction into 
glycosylation.  Chapter 2 the substrate specificity of FUT8 and chemo-enzymatic synthesis of 
core fucosylated asymmetric N-glycans published on Organic and Biomolecular Chemistry. 
Chapter 3 a review on FUT8: from biochemistry to synthesis of core-fucosylated N-glycans 
accepted for publication on Pure and Applied Chemistry.  Chapter 4 is a manuscript in progress 
for the enzymatic separation of asymmetric N-glycan isomers using FUT8 and Gn-T V substrate 
specificity.  Additional information on Gn-T I, II, and III can be found in Appendix A.  
1.2 Introduction 
Post-translational modifications are very important since they influence folding, stability, 
signaling, transport and life span of proteins. 8, 9 There are four types of glycosylated proteins 
known as glycoproteins: O-linked, N-linked, glycosaminoglycans, and 
glycosylphosphatidylinositol (GPI)-anchored proteins(Figure 1.2.1).10  
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Figure 1.2.1 Glycosylation types.  
 
 
Here we will only focus on N-linked glycosylation.  There are three types of N-glycans in 
a mature glycoprotein: oligomannose, complex, and hybrid (Figure 1.2.2).  Each N-glycan 
contains the common core Man3GlcNAc2Asn.8  Research has been done previously in order to 
determine the glycosylation site Asn-X-Ser/Thr.8, 11  Some amino acids have been found to 
inhibit glycosylation at the X position such as Pro. 
 
Figure 1.2.2 N-glycan structures found in mature glycoprotein.  
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1.3 Glycosylation importance 
Glycosylation of proteins often aids with folding and stability of secreted proteins. 
Oligosaccharides are important in many recognition, signaling and adhesion events within and 
between cells. Glycans have an important role in the biological function of proteins such as 
molecular stability, solubility, in vivo activity, serum half-life, and immunogenicity.10, 12-17 One 
important aspect of protein glycosylation is the function of the sialic acid component of the 
glycan.  Sialic acids on carbohydrates form highly hydrophilic structures, therefore increasing 
the solubility of the proteins by shielding hydrophobic residues.  They also have the ability to 
extend the half-life of proteins, which is very important for protein therapeutics.  Glycans can 
also reduce the susceptibility to proteolysis, and the sensitivity to thermal denaturation as it has 
been shown for glycosylated interferon beta (IFN-b).10 Another advantage with glycosylation is 
the potential to minimize the immune response that might be provoked by the generation of 
neutralizing antibodies against the engineered protein.10  Glycosylation is likely to reduce the 
immune response by increasing solubility and reducing aggregation.  It can also inhibit the 
antibody binding by “shielding” the protein sequences from the immune system. The glycan 
shielding protects the engineered protein sequence from immune surveillance.10 
1.4 N-Glycosylation site 
The commonly known N-glycosylation sequon known as Asn-X-Ser/Thr is many times 
poorly glycosylated or not glycosylated at all.8  This inefficiency in N-linked glycosylation led 
scientist to elucidate more on the required sequon for N-glycosylation.  Using cassette 
mutagenesis approach a group was able to identify a more specific N-glycosylation sequon.  
Their proposed sequon adds an additional term Y to the known one and examines amino acids 
that are favorable at the X and Y positions for the increase in N-glycosylation efficiency. 11  
15 
 
From previous reports it is known that this specific sequon can be improved by replacing Leu38 
with more favorable amino acid as well as replacing Ser39 with Thr can improve the 
glycosylation. The conclusion from these studies showed that position Y amino acid is actually 
important in order to increase the core glycosylation efficiency, especially when Ser is the 
hydroxyl amino acid.   From their results they were able to determine that Pro, Trp, and Glu 
inhibit glycosylation when present at the Y position just like they do when present at the X 
position.  They also suggest that large side groups may block how accessible the 
oligosaccharyltransferase and/or dolichol oligosaccharide donors are.  It may also form an 
unfavorable local protein conformation.  The effect of charge amino acids at the X and Y 
position is complex.  While Glu inhibits glycosylation, Asp only has some inhibitory effect not 
as notable as Glu.  Positively charged amino acids Arg appears to be the most favorable at Y 
position compared to His or Lys.  The most favorable amino acids at both positions X and Y are 
Thr, Ser and Cys.  From the study they suggest that probably the most favorable amino acids 
with side chains containing hydroxy or sulfhydryl can facilitate the catalytic reactions that 
involve Asn and Ser/Thr positions.11        
1.5 N-Glycosylation difference 
The N-glycan pathway is very conserved including the generation and transfer of 
Glc3Man9GlcNAc2 from dolichol phosphate to asparagine residues on newly synthesized 
proteins. Even though, glycans are found in all organism there is a lot of diversity in the structure 
and expression among all organism.  N-glycan pathway is found throughout all eukaryotes, but 
recently there is data indicating that some bacteria such as Campylobacter jejuni can also express 
similar N-glycan structures.   Glycans expressed by most free-living eubacteria and archaea have 
very little in common structurally with those of eukaryotes. 18		
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1.6 Protein glycosylation pathway 
It has been established that the major site for protein glycosylation is the endoplasmic 
reticulum (ER) followed by the golgi apparatus.  These two cell organelles form an 
endomembrane assembly line on which membrane-bound glycosyltransferases and glycosidases 
process the N-glycans attached to Asn key glycosylation site of the protein as they move towards 
their final destination (secretion, cell surface or lysosome).19  The Asn-GlcNAc bond is primarily 
formed on the nascent polypeptide while it is assembled into the ER by a membrane-bound 
ribosome. Complex N-glycans come from Glc3Man9GlcNAc2-pyrophosphate-dolichol, a lipid 
linked oligosaccharide (LLO), by a very extensive N-glycan processing pathway.8, 19  The 
synthesis of complex N-glycan proteins can be divided into three stages.  First is the formation of 
Glc3Man9GlcNAc2-pyrophosphate-dolichol between the cytoplasm and the rough ER lumen.  
The second stage takes place in the ER and is the transfer of Glc3Man9GlcNAc2 from 
pyrophosphate-dolichol to the Asn key glycosylation site on the nascent protein (Asn-X-Ser/Thr-
Y) which is catalyzed by Oligosaccharyltransferase (OST).  The third stage takes place in the cis, 
medial, and trans sections of the golgi apparatus. This stage is mostly found in eukaryotes since 
it requires a transfer of a GlcNAc residue with a b-1,2 linkage to the Man-a-1,3 branch.  This 
reaction is catalyzed by Gn-T I and followed by mannosidase II and Gn-T II to yield hybrid or 
complex N-glycans from oligomannose N-glycans (Figure 1.6.1). 8, 19 
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Figure 1.6.1 Summary of  processing and maturation of an N-glycan protein from the ribosome through 
the ER and Golgi apparatus to its final destination.8 
 
After the transfer of Glc3Man9GlcNAc2 glycan to Asn on the nascent protein, 
glucosidases in the ER remove the three glucose residues, and mannosidases remove the 
mannose residues. Glucosidases and mannosidase are associated with the folding of the 
glycoprotein, which is aided by a couple of lectins that will determine if the glycoprotein goes to 
the Golgi or is degraded. If the glycoprotein is misfolded the ER degradation-enhancing α-
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mannosidase I–like protein (EDEM) will bind to mannose residues and transport it to the 
cytoplasm for degradation.  The removal of additional mannose residues takes place at the cis-
Golgi apparatus until the core N-glycan is formed (Man5GlcNAc2Asn).  The formation of the bi-
anternnary N-glycan starts at the medial-Golgi with the action of Gn-T I adding a GlcNAc at the 
a-1,3 mannose followed by α-Mannosidase II to remove two mannoses.  Gn-T II then adds 
another GlcNAc at the a-1,6 mannose branch (Figure 1.6.1). The bi-antennary N-glycan can be 
further extended by addition of fucose, galactose, and sialic acid to generate a complex N-glycan. 
Complex N-glycans can also have addional branching and extesion.8 
1.7 Therapeutic N-linked glycoproteins 
Many important therapeutic proteins are glycosylated including Erythropoetin (EPO), 
granulocyte macrophage colony stimulating factor (GM-CSF) and some monoclonal antibodies 
(mAb) such as Etanercept, Infliximab and Rituximab.9  Therapeutic drugs glycosylation is very 
important as it was previously discussed.  One example of the importance is EPO.  Experiments 
performed on EPO glycosylated analogs have shown a direct relationship between the number of 
glycan chains and the increase in in vivo activity.  The increase in biological efficiency of 
glycosylated proteins can be due to the increase in serum half-life or circulating residence time.10 
The increase in biological activity efficiency was shown in recombinant human erythropoietin 
(rHuEPO).  Darbepoetin alfa (DA) a hyperglycosylated analogue of rHuEPO, shows a three fold 
increase in serum half-life when compared to rHuEPO. 10 
Rituximab is another great example of N-glycosylation importance for protein drugs 
biological activity enhancement.  This protein drug is a monoclonal antibody (mAb) against 
CD20.   mAbs are one of the fastest growing classes of pharmaceutical products. They are used 
to treat conditions such as cancer, infectious diseases, allergies, inflammation, and auto-immune 
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diseases.  Rituximab was approved in 1997 by the FDA as cancer therapy for the treatment of 
malignant lymphomas.  Rituximab is made up of 2 light chains containing 213 amino acids and 2 
heavy chains with 451 amino acids.  It has 12 intrachain disulfide linkages and 4 interchain 
disulfide linkages.  Rituximab only contains one glycosylation site on both heavy chains at 
Asn297 .20,21  The efficiency of this mAb is greatly influenced by the diversity and abundance of 
each glycan structure. Mass spectroscopy (MS) is an essential tool widely use in the 
pharmaceutical industry for the characterization of mAbs in order to gain FDA approval. MS is 
useful for determination of molecular weight of intact proteins, glycosylation location, glycan 
structure abundance, and amino acid sequence confirmation.20  Therefore, efficient access to 
well-defined glycan structures as strandards in glycomic research is very useful in the 
pharmaceutical industry.  
1.8 References: 
1. K. Kamio, T. Yoshida, C. Gao, T. Ishii, F. Ota, T. Motegi, S. Kobayashi, R. Fujinawa, K. 
Ohtsubo, S. Kitazume, T. Angata, A. Azuma, A. Gemma, M. Nishimura, T. Betsuyaku, 
K. Kida and N. Taniguchi, Biochem Biophys Res Commun, 2012, 424, 112-117. 
2. T. Fukuda, H. Hashimoto, N. Okayasu, A. Kameyama, H. Onogi, O. Nakagawasai, T. 
Nakazawa, T. Kurosawa, Y. Hao, T. Isaji, T. Tadano, H. Narimatsu, N. Taniguchi and J. 
Gu, J Biol Chem, 2011, 286, 18434-18443. 
3. E. Miyoshi, K. Noda, Y. Yamaguchi, S. Inoue, Y. Ikeda, W. Wang, J. H. Ko, N. Uozumi, 
W. Li and N. Taniguchi, Biochim Biophys Acta, 1999, 1473, 9-20. 
4. H. Imai-Nishiya, K. Mori, M. Inoue, M. Wakitani, S. Iida, K. Shitara and M. Satoh, BMC 
Biotechnol, 2007, 7, 84. 
5. X. Wang, J. Chen, Q. K. Li, S. B. Peskoe, B. Zhang, C. Choi, E. A. Platz and H. Zhang, 
Glycobiology, 2014, 24, 935-944. 
6. L. Li, Y. Liu, C. Ma, J. Qu, A. D. Calderon, B. Wu, N. Wei, X. Wang, Y. Guo, Z. Xiao, 
J. Song, G. Sugiarto, Y. Li, H. Yu, X. Chen and P. G. Wang, Chemical science, 2015, 6, 
5652-5661. 
7. S. Serna, S. Yan, M. Martin-Lomas, I. B. Wilson and N. C. Reichardt, Journal of the 
American Chemical Society, 2011, 133, 16495-16502. 
8. R. D. Cummings and J. D. Esko, in Essentials of Glycobiology, eds. A. Varki, R. D. 
Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart and M. E. 
Etzler, Cold Spring Harbor (NY), 2nd edn., 2009. 
20 
 
9. M. Kuhlmann and A. Covic, Nephrology, dialysis, transplantation : official publication 
of the European Dialysis and Transplant Association - European Renal Association, 
2006, 21 Suppl 5, v4-8. 
10. A. M. Sinclair and S. Elliott, Journal of pharmaceutical sciences, 2005, 94, 1626-1635. 
11. J. L. Mellquist, L. Kasturi, S. L. Spitalnik and S. H. Shakin-Eshleman, Biochemistry, 
1998, 37, 6833-6837. 
12. R. A. Dwek, Chemical reviews, 1996, 96, 683-720. 
13. B. Imperiali and S. E. O'Connor, Current opinion in chemical biology, 1999, 3, 643-649. 
14. A. Helenius and M. Aebi, Science, 2001, 291, 2364-2369. 
15. A. Helenius and M. Aebi, Annual review of biochemistry, 2004, 73, 1019-1049. 
16. A. Varki and J. B. Lowe, in Essentials of Glycobiology, eds. A. Varki, R. D. Cummings, 
J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart and M. E. Etzler, Cold 
Spring Harbor (NY), 2nd edn., 2009. 
17. Y. Y. Zhao, M. Takahashi, J. G. Gu, E. Miyoshi, A. Matsumoto, S. Kitazume and N. 
Taniguchi, Cancer science, 2008, 99, 1304-1310. 
18. R. D. Cummings and J. D. Esko, in Essentials of Glycobiology, eds. A. Varki, R. D. 
Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart and M. E. 
Etzler, Cold Spring Harbor (NY), 2nd edn., 2009. 
19. H. Schachter, Glycoconjugate journal, 2000, 17, 465-483. 
20. M. Samonig, C. Hber and K. Scheffler, Thermo Fisher Scientific Application Note 591, 
1-11. 
21. V. H. Pomin, Unravelling Glycobiology by NMR Spectroscopy, 2012. 
 
21 
 
2 SUBSTRATE SPECIFICITY OF FUT8 AND CHEMOENZYMATIC SYNTHESIS 
OF CORE-FUCOSYLATED ASYMMETRIC N-GLYCANS  
The work presented in this chapter is reproduced with some modification as to fit the 
format with permission from journal: “Substrate Specificity of FUT8 and Chemoenzymatic 
Synthesis of Core-fucosylated Asymmetric N-glycans.” Angie D. Calderon, Yunpeng Liu, Xu 
Li, Xuan Wang, Xi Chen, Lei Li and Peng G. Wang. Organic and Biomolecular Chemistry. 
(2016) 14 (17) 4027-3. 
2.1 Abstract 
Substrate specificity studies of human FUT8 using 77 structurally-defined N-glycans as 
acceptors showed a strict requirement towards the a1,3-mannose branch, but a great promiscuity 
towards the a1,6-mannose branch. Accordingly, a chemo-enzymatic strategy was developed for 
efficient synthesis of core-fucosylated asymmetric N-glycans. 
2.2 Introduction 
Asparagine-linked glycosylation (N-glycosylation) represents the most prevalent and 
structurally varied post-translational modification of eukaryotic proteins. Tremendous advances in 
glycobiology have demonstrated that asparagine-linked oligosaccharides (N-glycans) can 
modulate protein’s structure and function in many ways. For example, they were found to play 
roles in a variety of biological processes, including cell adhesion, pathogen infections, immune 
responses and tumor metastasis.1-3 On the other hand, N-glycans can influence proteins 
biosynthesis, folding, stability, antigenicity and immunogenicity.3-6 N-Glycans found in nature 
possesses inherent complexity and diversity, due to variable connectivity of monosaccharide 
building blocks as well as additional modifications on the basic scaffolds. Core-fucosylation is a 
major N-glycan modification in eukaryotic glycomes. 
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In mammalian cells, core-fucosylation is exclusively found as a1,6-fucosylation of the 
innermost N-acetyl-glucosamine (GlcNAc) residue of N-glycans. Many glycoproteins are known 
to be core-fucosylated, and accumulating data indicate that this type of modification regulates the 
functions of certain glycoproteins. For example, depletion of N-glycan core-fucosylation in human 
IgG1 enhanced its antibody-dependent cytotoxicity (ADCC) activity to 50 - 100 folds.7, 8 It was 
shown that core-fucosylation regulates the functions of immunoglobulin by altering its 
physicochemical properties.9 Another most recent example is that in humoral immune response, 
core-fucosylation of IgG B cell receptor was shown to mediate antigen recognition and cell signal 
transduction.10 Alteration of core-fucosylation is frequently found to be closely related to human 
diseases including liver cancer, pancreatic cancer, lung cancer, breast cancer, etc.11, 12 A well-
known example is a-fetoprotein, which was found highly core-fucosylated specifically in 
hepatocellular carcinoma, but not other liver diseases.13-16 In addition, E-cadherin, a glycoprotein 
correlated with cancer metastasis, was found to be core-fucosylated in highly metastatic lung 
cancer cells but absent in low metastatic ones.17 Compare to controls, increased core-fucosylated 
N-glycans and decreased non-fucosylated ones were also detected in the clinical ovarian cancer 
biomarker CA125.18  Moreover, core-fucosylation is pivotal in development, and the loss of such 
N-glycan modification leads to severe phenotypes such as growth retardation, emphysema-like 
changes in lung, even death.19 All these evidences strongly suggest that core-fucosylation plays 
vital roles in various biological processes and events.   
FUT8 is the only enzyme responsible for core-fucosylation in mammals, which catalyzes 
the transfer of an L-fucose residue from GDP-b-L-fucose (GDP-Fuc) onto the innermost GlcNAc 
of N-glycan to form an a1,6-linkage (Figure 2.2.1).19, 20 It has been reported that FUT8 is highly 
expressed in brain tissue (where core-fucosylated glycoproteins were found abundant), human 
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blood platelets, cancer tissues, and other tissues during certain pathological processes. Previous 
substrate specificity study suggested that FUT8 requires both a1,3-mannose branch terminal 
GlcNAc residue and reducing end b-configuration of the acceptor.21-24 In addition, galactosylation 
of the GlcNAc residue at a1,3-mannose branch and bisecting of N-glycans prevent FUT8 
activity.21, 22 Most recently, we and others showed that both human and Caenorhabditis elegans 
FUT8 can fucosylate asymmetric N-glycans (Figure 2.2.1, N211 and N212), indicating that they 
may have a much relaxed acceptor substrate preference towards the a1,6-mannose branch.25, 26 A 
comprehensive study is necessary to confirm such specificity, and structurally defined N-glycans 
that we synthesized previously26 represent perfect substrate candidates for test.  
Given the significance, FUT8 and core-fucosylation have been extensively investigated in 
terms of glycomics and in vivo biological functions, while in depth molecular elucidation is 
largely limited by the unavailability of structurally well-defined N-glycans with core-
fucosylation. In the past decade, a few chemical and enzymatic methodologies were developed 
for the preparation of such molecules. Unverzagt, used a modular chemical synthesis strategy 
where the a1,6-fucose was attached in the last step.27-29 On the other hand, Huang applied a pre-
activation-based one-pot chemical strategy to quickly assemble a dodecasaccharide N-glycan 
structure.30 Enzymatically, Reichardt used C. elegans FUT8 to core-fucosylate chemically 
prepared simple N-glycan structures (Figure 2.2.1, N000 and N010),31 while Wang applied 
glycosynthases to conjugate chemically prepared glycan oxazolines and Fuca1,6-GlcNAc to 
form homogeneous core-fucosylated N-glycans and glycoproteins.32, 33 In all cases, only simple 
or symmetric core-fucosylated N-glycans were prepared, and an efficient strategy for rapid 
access of more complicated and asymmetric ones is yet to be developed. In this work, human 
FUT8 was overexpressed and purified, detailed acceptor substrate specificity was investigated 
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towards 77 structurally defined N-glycans and derivatives. Accordingly, a chemoenzymatic 
strategy was developed for efficient synthesis of core-fucosylated asymmetric N-glycans.
 
Figure 2.2.1 FUT8 catalyzed reaction and substrate specificity of human FUT8 using 77 N-glycans as 
potential acceptors (see Figure 2.6.3 for the full list of N-glycans, Table 2.6.3.1 for conversion 
percentage towards each glycan). The average conversion percentage of three replicates for each acceptor 
was shown. 
 
2.3 Results and Discussion 
Human FUT8 was chosen for substrate specificity study and synthetic purpose. 
Heterogeneous expression was achieved via a Titerless Infected-cell Preservation and Scale-up 
(TIPS) approach34 using a baculovirus system (see http://glycoenzymes.ccrc.uga.edu for system 
and construction details) provided by Dr. Jarvis from the University of Wyoming.  After one-step 
Ni-Sepharose Excell (GE Healthcare) affinity purification, recombinant FUT8 with a purity of 
over 90% (Figure 2.6.1) was obtained in a scale of 0.42 mg/L of cultures. Substrate specificity 
study was then performed in reactions with a total volume of 20 µL containing an acceptor N-
glycan (0.3 mM), donor GDP-Fuc (1 mM), MES buffer (100 mM, pH 7.0) and 50 µg/mL of the 
recombinant human FUT8.  After 4 h of incubation at 37 °C, the reactions were quenched by the 
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addition of equal volumes of ice cold ethanol, followed by analysis using mass spectrometry (MS) 
and high performance liquid chromatography (HPLC) monitored by an evaporative light scattering 
detector (ELSD) (See pg. 33 § 2.6.3).  
Consistent with previous reports21-24 as shown in Figure 2.2.1, FUT8 could core-fucosylate 
N-glycans with an agalactosylated and unprotected GlcNAc residue on the a1,3-mannose branch 
(N000, N010, N020, N030, N110, and N211-N215), but not those either galactosylated or with 
protected GlcNAc residue on the branch. Among these N-glycans, FUT8 showed the highest 
activity towards biantennary complex N-glycan structures terminated with GlcNAc at the non-
reducing end of both a1,3- and a1,6-mannose branches N000 (91.3% conversion) and slightly 
decreased activities towards N110 (63.4% conversion) and N211-N213 (67.8% to 70.4% 
conversion), indicating that galactosylation with or without additional sialylation or chemical 
protection of GlcNAc on the a1,6-mannose branch can be well tolerated. The addition of an a1,3-
linked fucose to the terminal N-acetyllactosamine (LacNAc) or sialyl LacNAc structures on N211 
and N212 to form the Lewis x and sialyl Lewis x structures on the a1,6-mannose branch of N214 
(40.1%) and N215 (34.8%), respectively, further decrease the efficiency for FUT8-catalyzed core 
fucosylation. Quite interestingly, FUT8 was found to be able to glycosylate N04, an N-glycan 
without a a1,3-mannose branch, even though with a neglectable percentage conversion (5.26%). 
The result was confirmed by milligram scale synthesis and product N604 purification followed by 
mass spectrometry (MS) and proton nuclear magnetic resonance (1H NMR) characterization (See 
pg. 53 § 2.6.6). Overall, our substrate specificity study using a library of 77 structurally defined 
N-glycans confirmed that FUT8 has a quite strict requirement towards the a1,3-mannose branch, 
and suggested a very relaxed preference towards the a1,6-mannose branch.  
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With the information about substrate specificity of FUT8 in hand, we were ready to design 
effective routes for synthesizing asymmetric N-glycans with core-fucosylation which have been 
frequently found in the glycomes of mammalian cells, especially on disease related proteins.35-37 
For example, putative structures of m/z 2605 and 2780 found on human ovarian biomarker 
glycoprotein CA125 were determined by matrix-assisted laser desorption/ionization-mass 
spectrometry (MALDI-MS) and collision activated dissociation-tandem mass spectrometry (CAD-
MS/MS).38 Nevertheless, a few possible isomers (Figure 2.3.1) were not ruled out. To access such 
asymmetric N-glycans with core-fucosylation which can be used as glycan standards, a facile 
chemoenzymatic synthetic strategy was developed (Figure 2.3.2 and  
Figure 2.3.3).  
Similar to our core synthesis/enzymatic extension strategy (CSEE) for the preparation of 
asymmetric N-glycans,26 we envisaged N6111 and N6211 as two key intermediates for the 
synthesis of core-fucosylated ones. As illustrated in Figure 2.3.2A, to obtain intermediate N6111, 
Figure 2.3.1 Two N-glycans (m/z) identified from CA125 and possible N-glycans (black squared). 
Red dash squared N-glycan structures were synthesized in this study. 
27 
 
we chose chemically prepared N-glycan N110 26 as a starting point, which was shown to be an 
well tolerated substrate of human FUT8 in the substrate specificity study described above. Briefly, 
in a 2.5 mL reaction system containing 100 mM MES buffer (pH 7.0), 7.2 mg (5 µmole, 2 mM) 
of N110 was incubated at 37 °C with GDP-Fuc (4 mM), recombinant FUT8 (0.2 mg/mL), and 10 
U/mL of thermosensitive alkaline phosphatase (FastAP, ThermoFisher) to drive the reaction 
forward by digesting byproduct GDP. Every other hour, 2 µL of the reaction mixture was 
withdrawn for analysis. MALDI-MS analysis showed a peak at m/z = 1611.5695, corresponding 
to N6110 [M + H]+. Meanwhile, on the HPLC-ELSD profile, a new peak (TR = 6.99 min) was 
observed, of which the area increased while that of the peak corresponding to N110 (TR = 6.06 
min) decreased. After N110 was completely fucosylated (8 h incubation), the reaction was freeze-
quenched at -80 °C for 30 min, and the mixture was concentrated to 300 mL for HPLC purification 
with a water/acetonitrile gradient elution (See pg. 36 § 2.6.4 for details) to provide 6.9 mg of 
N6110 (87% yield). The purified N6110 was then galactosylated to afford N6111a by bovine b1,4-
galactosyltransferase (b4GALT1) as described previously.26 In this case, only the GlcNAc residue 
on the a1,3-mannose branch was galactosylated, as the other one on the a1,3-mannose branch was 
protected by peracetylation. After HPLC purification, the GlcNAc residue on the a1,6-mannose 
branch of N6111a was de-acetylated with 3% of ammonium hydroxide to afford 6.5 mg (after 
HPLC purification) of key intermediate N6111 (80% yield over 3 steps).  
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Figure 2.3.2 Chemoenzymatic synthesis of core-fucosylated asymmetric N-glycans from N110 (A), 
and MALDI-MS analysis of purified glycans (B). Reaction conditions: a) FUT8, GDP-Fuc, FastAP; 
b) b4GALT1, UDP-Gal, FastAP, Mn2+; c) 30% ammonium hydroxide : H2O (1 : 10), 6 h; d) 
PmST1m, CMP-Neu5Ac; e) Pd2,6ST, CMP-Neu5Ac; f) Hpa1,3FT, GDP-Fuc, FastAP, Mn2+. FUT8, 
human a1,6-fucosyltransferase; b4GALT1, bovine b1,4-galactosyltransferase; PmST1m, Pasteurella 
multocida a2,3-sialyltransferase 1 mutant E271F/R313Y; Pd2,6ST, Photobacterium damselae a 2,6-
sialyltransferase; Hpa1,3FT, c-terminal 66 amino acids truncated Helicobacter pylori a1,3-
fucosyltransferase; FastAP, thermo-sensitive alkaline phosphatase.  
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With N6111 in hand, core-fucosylated asymmetric N-glycans N6122, N6123 and N6244 
were prepared in a step-wise manner similar to that of the non-core-fucosylated ones.26 Besides 
b4GALT1, 3 bacterial glycosyltransferases (GTs) were employed in the synthesis, including a 
sialidase activity reduced mutant (E271F/R313Y) of Pasteurella multocida a2,3-sialyltransferase 
1 (PmST1m)39 to catalyze the formation of a2,3-sialosides, a Photobacterium damselae a2,6-
sialyltransferase (Pd2,6ST)40 to catalyze the formation of a2,6-sialosides, and a C-terminal 66 
amino acids truncated version of Helicobacter pylori a1,3-fucosyltransferase (Hpa1,3FT)26 to 
fucosylate branched GlcNAc residues (Figure 2.3.2A). All glycans were purified by HPLC after 
each glycosylation step and characterized by MALDI-MS (Figure 2.3.2B).  N-Glycan purity was 
confirmed by HPLC-ELSD (See pg. 37 § 2.6.5). It is worth to mention that none of the 4 GTs 
showed altered activity towards core-fucosylated N-glycan substrates compare to that for non-
core-fucosylated ones, indicating that the a1,6-core fucose has negligible effect on acceptor glycan 
interaction with the GTs. More core-fucosylated asymmetric N-glycans can thus be readily 
synthesized from N6111 following previously reported routes.26 
 
Figure 2.3.3 Enzymatic synthesis of core-fucosylated N-glycans starting with N210. (See Figure 2.3.2A) 
for detailed description of each step. 
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In contrast to N110 with a per-acetylated GlcNAc at the a1,6-mannose branch which is a 
suitable acceptor for FUT8, N210 with a per-acetylated GlcNAc at the a1,3-mannose branch is 
not a suitable substrate for FUT8. Therefore, a key intermediate N6211 was needed for further 
enzymatic extension. It was synthesized from N210 by b1,4-galactosylation of the non-protected 
GlcNAc on the a1,6-mannose branch for the formation of N211 followed by deprotection of the 
GlcNAc on the a1,3-mannose branch and FUT8-catalyzed core-fucosylation of the asymmetric 
N-glycan ( 
Figure 2.3.3).  Starting from N6211, desired N-glycans N6222, N6223 and N6144 were then 
enzymatically synthesized in a step-wise manner as described above ( 
Figure 2.3.3). The purified products were characterized by MALDI-MS, 1H NMR (See pg. 
37 § 2.6.5), 1H NMR (See pg. 54 § 2.6.7), and HPLC-ELSD (See pg. 37 § 2.6.5).  
2.4 Conclusion 
In conclusion, the available of previously synthesized 77 structurally-defined N-glycans 
allowed detailed substrate specificity study of a recombinant human FUT8. Results showed a quite 
strict requirement of FUT8 towards the a1,3-mannose branch but a great promiscuity towards the 
a1,6-mannose branch. Interestingly, human FUT8 can also core-fucosylated an N-glycan without 
the a1,3-mannose branch, which was not observed before. In addition, a facile chemo-enzymatic 
strategy was developed and employed for the efficient synthesis of a panel of core-fucosylated 
asymmetric N-glycans. These well-defined structures are valuable standards and probes for 
glycomics analysis and elucidating functions of glycan-binding protein.  
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2.6 Experimental 
2.6.1 Materials and enzymes 
b1,4-galactosyltransferase from bovine milk (B4GALT1) was purchased from Sigma. 
Thermosensitive Alkaline Phosphatase (FastAP) was purchased from Thermo Scientific. N,N’-
diacetyl-chitobiose (N01) was purchased from Sigma, and N-glycans N02, N03, N04, N05, N06 
were purchased from V-labs (Covington, LA). Other enzymes including double mutant 
E271F/R313Y from Pasteurella multocida a2,3-sialyltransferase 1 (PmST1m)39, a2,6-
sialyltransferase from Photobacterium damslae (Pd2,6ST)40, C-terminal 66 amino acids truncated 
Helicobacter pylori a1,3-fucosyltransferase (Hpa1,3FT)41, CMP-sialic acid synthetase from N. 
meningitidis (NmCSS)42 were expressed and purified as previously described. Enzymes were then 
desalted against 50 mM Tris-HCl, 100 mM NaCl, and 50% glycerol, and stored at -20 °C for long 
term use. Sugar nucleotides uridine 5’-diphospho-galactose (UDP-Gal)43, cytidine 5’-
monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)42 and guanosine 5’-diphospho-L-fucose 
(GDP-Fuc)44 were prepared as described previously. 
2.6.2 Expression and purification of human FUT8 
2.6.2.1 Cryopreservation and maintenance of Baculovirus infected Sf9 cells  
The 50 µL of P1PP1 baculovirus stock and Sf9 cells for the expression of the FUT8 were 
kindly provided by Dr. Donald Jarvis from University of Wyoming. For the Titerless Infected-
cells Preservation and Scale-up (TIPS) expression method34, a primary stock of cryopreserved 
infected cells BIIC was prepared by infecting 25 mL of Sf9 cells at a concentration of 1×106 C/mL 
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with 25 µL of untitered liquid P1PP1 baculovirus stock (an estimated MOI of approximately 3 
pfu/cell). The cells were cryopreserved when the average diameter increases by 20-30% of their 
pre-infected diameter and the viability was above 95%.  Sf9 cells were grown and infected at 28 
°C and 150 rpm in complete TNM-FH medium [TNM-FH medium (Sigma-Aldrich), 
supplemented with 10% Fetal Bovine Serum (FBS) (BioWest), 0.5% antibiotic-antimycotic 
(Sigma-Aldrich), and 0.1% Pluronic-F68 (Invitrogen)].  The cells were cryopreserved at a density 
of 1×107 C/mL in liquid nitrogen and complete TNM-FH medium and 10% DMSO (Sigma-
Aldrich). Cell density was determined by hemocytometer counts, and the cell viability was 
evaluated by Trypan Blue staining.  
2.6.2.2 FUT8 expression and purification  
Sf9 cells were infected at a cell density of 1×106 C/mL. The baculovirus titer was estimated 
using insect cell density at time of infection and a conservative cellular baculovirus maximum 
production rate of 100 pfu/cell for 1×106 C/mL meaning 1×108 pfu/mL.  BIIC stock was thawed 
in a 37 °C water bath and diluted 1:100 into cell-free medium, then 10 mL of infected cell-free 
medium was added to 1 L of uninfected cells (1:1000 dilution)34. The medium was collected after 
72 h of expression followed by purification.  The purification of the secreted protein was 
accomplished by diluting the medium 1:1 with equilibration buffer (50 mM Tris-HCl, pH 7.5, 0.5 
M NaCl) and loading to 2 mL of pre-equilibrated Ni-Sepharose Excell (GE Healthcare)45. The 
column was rinsed using 200 mL of wash buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 50 mM 
imidazole), and finally eluted with 5 mL of elution buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 
250 mM imidazole). The enzyme was desalted and concentrated using Amicon YM-30 
ultrafiltration membrane (Millipore) against desalting buffer (50 mM Tris-HCl pH 7.5). Purified 
FUT8 was confirmed by SDS-PAGE (>90% pure) and western blot (Figure 2.6.1). Using TIPS 
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method 0.42 mg of human FucT8 were purified from 1 L cultures as determined using Bradford 
method. The activity of recombinant FUT8 was confirmed by using N000 as a substrate, monitored 
by MS (Figure 2.6.2). 
 
Figure 2.6.1 SDS-PAGE and western blot analysis of FUT8. 1) SDS-PAGE of medium after 
overexpression of FUT8; 2) SDS-PAGE of purified FUT8; and 3) western blot analysis of purified FUT8 
using anti-His antibody as the primary antibody. BSA, a major protein component of Fetal Bovine Serum 
used in the culture medium, has similar molecular weight as that of FUT8. 
 
 
Figure 2.6.2 MALDI-MS analysis of FUT8 catalyzed reaction using N000 as substrate. Majority of N000 
(molecular weight 1316.4865, found M+Na 1339.4568) was converted into core-fucosylated one 
(molecular weight 1462.5444, found M+Na 1485.5385). 
2.6.3 Substrate specificity study of FUT8 
A detailed substrate specificity study of FUT8 was performed using 77 chemically or 
chemo-enzymatically synthesized, or commercially available N-glycans (with free reducing end) 
as acceptors (Figure 2.6.3). Reactions were performed in a 96 well PCR plate, with each well (20 
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µL total volume) contains one N-glycan substrate (0.3 mM, 2.5 µg to 15.1 µg), GDP-Fuc (1 mM), 
FUT8 (0.05 mg/mL) and MES buffer (100 mM, pH 7.0). Reactions were incubated at 37 °C for 4 
h in an Eppendorf thermocycler (Mastercycler Pro), followed by enzyme inactivation at 95 °C for 
20 min. A negative control was also set up using N000 as substrate without enzyme. After 
centrifugation (13,000 g for 10 min), the supernatant was analyzed by HPLC using an analytical 
Waters XBridge BEH amide column (130 Å, 5 µm, 4.6 x 250 mm), detected by an evaporative 
light scattering detector (Shimadzu ELSD-LTII). Gradient elution (%B: 75– 60% for glycans with 
less than 9 monosaccharides, 70– 55% for glycans with 9 or more monosaccharides) was 
performed with Solvent A (100 mM ammonium formate, pH 3.4) and Solvent B (Acetonitrile). 
The percent yields (average of three replicated reactions, see (Table 2.6.3.1) were calculated as % 
= Product peak area/ (Product peak area + Substrate peak area) × 100.  
Table 2.6.3.1 Substrate specificity of FUT8. ND, Not Detected. Conversions were monitored by HPLC-
ELSD, average of three replicates were shown. 
 
Glycan substrate Conversion (%) 
N04 5.26 
N010 75.6 
N020 49.8 
N030 32.8 
N000 91.3 
N110 63.4 
N210 ND 
N211 67.8 
N212 69.4 
N213 70.4 
N214 40.1 
N215 34.8 
All other N- 
glycans 
ND 
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Figure 2.6.3 The 77 N-glycans used as acceptor for FUT8 substrate specificity study. The preparation and 
characterization of all substrates were published previously6.  The ones in the red square were found to be 
suitable acceptors for FUT8. 
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2.6.4 General methods for glycan synthesis and purification 
Reactions catalyzed by B4GALT1, Hpa1,3FT, PmST1m and Pd2,6ST were performed and 
monitored as we described previously26. Reactions catalyzed by FUT8 were performed in 100 mM 
MES buffer (pH 7.0), containing 2 mM glycan acceptor, 4 mM GDP-Fuc donor, FastAP (10 U/mL) 
and 0.1 mg/mL FUT8. Reactions were allowed to proceed for 6 h to overnight at 37 °C until 
substrates were totally converted to products (monitored by HPLC-ELSD as described above). The 
reactions were then quenched by freezing in -80 °C for 30 min, followed with concentration by 
lyophilization. HPLC-A210nm was then used to purify target glycans using a semi-preparative amide 
column (130 Å, 5 µm, 10 mm × 250 mm). The running conditions are solvent A: 100 mM 
ammonium formate (for glycans with Neu5Ac residues) or water (for glycans without Neu5Ac 
residues), pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 70-55% within 25 min. 
Products containing portions were then concentrated and lyophilized for characterization.  The 
purity of each glycan was confirmed by HPLC-ELSD using an analytical Waters amide column 
(130 Å, 5 µm, 4.6 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium 
formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min.  
The molecular weight of each N-glycans was confirmed by MALDI-MS performed on 
UltrafleXtreme MALDI TOF/TOF Mass Spectrometer (Bruker). Scan range of MS1 was according 
to the molecular weight of N-glycans, and reflector mode was used for N-glycan analysis. Mass 
spectra were obtained in both positive and negative extraction mode with the following voltage 
settings: ion source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage 
was set to 20 kV. The laser was pulsed at 7 Hz and the pulsed ion extraction time was set to 400 
ns. The laser power was kept in the 25–40% range. Structures of key intermediates and asymmetric 
N-glycans with core-fucosylation were confirmed by 1H NMR.   
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2.6.5  HPLC profiles and MS data of purified N-glycans 
N6110   (6.9 mg) 
   
MALDI-MS, calculated: 1588.5761; found [M+Na]+: 1611.5692, [M+K]+: 1627.1403 
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N6111a       (3.8 mg) 
  
 
MALDI-MS, calculated: 1750.6290; found [M+Na]+: 1773.6207, [M+K]+: 1789.2301 
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N6111      (3.5 mg) 
   
  
HPLC-ELSD, TR = 14.01 min 
 
 
MALDI-MS, calculated: 1624.5973; found [M+Na]+: 1647.5894 
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N6112      (1.0 mg) 
   
 
HPLC-ELSD, TR = 15.45 min 
 
 
 
MALDI-MS, calculated: 1915.6927; found [M-H]-: 1914.6880 
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N6113      (1.5 mg) 
   
 
HPLC-ELSD, TR = 16.73 min 
 
 
 
MALDI-MS, calculated: 1915.6927; found [M-H]-: 1914.6896 
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N6122      (0.8 mg) 
   
 
HPLC-ELSD, TR = 17.36 min 
 
 
 
MALDI-MS, calculated: 2077.7455; found [M-H]-: 2076.7399 
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N6123      (1.2 mg) 
   
 
HPLC-ELSD, TR = 18.36 min 
 
 
 
MALDI-MS, calculated: 2077.7455; found [M-H]-: 2076.7392 
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N6144      (0.8 mg) 
   
 
HPLC-ELSD, TR = 20.12 min 
 
 
 
MALDI-MS, calculated: 2223.8034; found [M-H]-: 2222.7993   
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N211a      (4.6 mg) 
   
MALDI-MS, calculated: 1604.5710; found [M+Na]+: 1627.5650 
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N211       (4.4 mg) 
   
MALDI-MS, calculated: 1478.5393; found [M+Na]+: 1501.5305, [M+K]+: 1517.5030 
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N6211      (4.0 mg) 
   
 
HPLC-ELSD, TR = 13.75 min 
 
 
 
MALDI-MS, calculated: 1624.5973; found [M+Na]+: 1647.5885, [M+K]+: 1663.5652 
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N6212       (1.3 mg) 
   
 
HPLC-ELSD, TR = 15.19 min 
 
 
 
MALDI-MS, calculated: 1915.6927; found [M-H]-: 1914.6891 
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N6213      (1.8 mg) 
   
 
HPLC-ELSD, TR = 16.51 min 
 
 
 
MALDI-MS, calculated: 1915.6927; found [M-H]-: 1914.6897 
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N6222      (0.9 mg) 
   
 
HPLC-ELSD, TR = 17.32 min 
 
 
 
MALDI-MS, calculated: 2077.7455; found [M-H]-: 2076.7422 
 
  
Datafile Name:N6222.lcd
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 min
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
mV
ELSD 
2076.7422
0.00
0.25
0.50
0.75
1.00
1.25
4x10
In
te
ns
. [
a.
u.
]
1300 1400 1500 1600 1700 1800 1900 2000 2100 2200
m/z
51 
 
N6223       (1.3 mg) 
   
 
HPLC-ELSD, TR = 18.39 min 
 
 
 
MALDI-MS, calculated: 2077.7455; found [M-H]-: 2076.7418 
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N6244      (0.9 mg) 
   
 
HPLC-ELSD, TR = 20.11 min 
 
 
 
MALDI-MS, calculated: 2223.8034; found [M-H]-: 2222.7986 
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2.6.6 ESI-MS and 1H NMR data of purified N604 
N604      (0.4 mg) 
   
ESI-MS, calculated: 894.3329; found [M+H]+: 895.3384, [M+Na]+: 917.3202 
 
 
1H NMR of N604 
1H NMR (D2O, 500 MHz): d 6.18 (s, 1 H), 6.17 (s, 1 H),4.65 (s, 1 H), 4.41 (brs, 2 H), 4.20-
4.30 (m, 5 H), 4.08-4.12 (m, 2 H), 4.56-4.00 (m, 20 H), 2.12 (s, 3 H, NHAc), 2.07 (s, 3 H, NHAc), 
1.25 (t, J = 5.4 Hz, 3 H, Fuc-CH3) 
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2.6.7 NMR spectra and data of purified core-fucosylated N-glycans 
1H NMR of N6122 
 
 
1H NMR (D2O, 500 MHz): d 5.17 (d, J = 2.9 Hz, 0.5 H, GlcNAc-1 H1 of a isomer), 5.11 
(s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.88 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of a isomer), 
4.87 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of b isomer), 4.75-4.80 (overlap with D2O, 1 H, Manb H-1), 
4.65-4.68 (m, 1.5 H, GlcNAc-1 H-1 of b isomer, GlcNAc-2 H-1), 4.57 (d, J = 7.9 Hz, 1 H, GlcNAc-
3 H-1), 4.56 (d, 1 H, J = 6.6 Hz, 1 H, GlcNAc-4 H-1), 4.53 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.46 
(d, 1 H, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.24 (brs, 1 H), 4.18 (d, J = 1.9 Hz, 1 H), 4.08-4.11 (m, 3 H), 
3.46-4.00 (m, 60 H), 2.75 (dd, J = 12.5, 4.6 Hz, 1 H, Neu5Ac H-3eq), 2.08 (s, 3 H, Ac), 2.04 (s, 6 
H, Ac), 2.03 (s, 3 H, Ac),2.02 (s, 3 H, Ac), 1.79 (t, J = 12.5 Hz, 1 H, Neu5Ac H-3ax), 1.21 (d, J = 
6.4 Hz, 1.5 H, Fuc H-6), 1.20 (d, J = 6.4 Hz, 1.5 H, Fuc H-6) 
 
55 
 
 
1H NMR of N6123 
 
 
1H NMR (D2O, 500 MHz): d 5.17 (d, J = 2.9 Hz, 0.5 H, GlcNAc-1 H-1 of a isomer), 5.12 
(s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.88 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of a isomer), 
4.87 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of b isomer), 4.75-4.85 (overlap with D2O, 1 H, Manb H-1), 
4.65-4.69 (m, 1.5 H, GlcNAc-1 H-1 of b isomer, GlcNAc-2 H-1), 4.59 (d, J = 7.9 Hz, 1 H, GlcNAc-
3 H-1), 4.57 (d, J = 7.8 Hz, 1 H, GlcNAc-4 H-1), 4.46 (d, 1 H, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.43 
(d, 1 H, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.24 (brs, 1 H), 4.18 (d, J = 1.8 Hz, 1 H), 4.07-4.09 (m, 2 H), 
3.46-4.00 (m, 61 H), 2.66 (dd, J = 12.5, 4.7 Hz, 1 H, Neu5Ac H-3eq), 2.08 (s, 3 H, Ac), 2.06 (s, 3 
H, Ac), 2.04 (s, 3 H, Ac),2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.71 (t, J = 12.5 Hz, 1 H, Neu5Ac H-
3ax), 1.21 (d, J = 6.3 Hz, 1.5 H, Fuc H-6), 1.20 (d, J = 6.3 Hz, 1.5 H, Fuc H-6) 
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1H NMR of N6144 
 
 
1H NMR (D2O, 500 MHz): d 5.16 (d, J = 2.8 Hz, 0.5 H, GlcNAc-1 H1 of a isomer), 5.10 
(d, J = 3.9 Hz, 1 H, Fuc-2 H-1), 5.09 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.87 (d, J = 3.7 
Hz, 0.5 H, Fuc H-1 of a isomer), 4.86 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of b isomer), 4.75-4.83 
(overlap with D2O, 1 H, Manb H-1), 4.65-4.68 (m, 1.5 H, GlcNAc-1 H-1 of b isomer, GlcNAc-2 
H-1), 4.56-4.58 (m, 2 H, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.41-4.43 (m, 2 H, Gal-1 H-1, Gal-2 H-
1), 4.23 (brs, 1 H), 4.17 (d, J = 1.9 Hz, 1 H), 4.07-4.12 (m, 3 H), 3.42-3.99 (m, 64 H), 2.65 (dd, J 
= 12.5, 4.7 Hz, 1 H, Neu5Ac H-3eq), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.01 
(s, 3 H, Ac), 2.00 (s, 3 H), 1.70 (t, J = 12.5 Hz, 1 H, Neu5Ac H-3ax), 1.21 (d, J = 6.3 Hz, 1.5 H, 
Fuc H-6), 1.20 (d, J = 6.3 Hz, 1.5 H, Fuc H-6), 1.15 (d, J = 6.5 Hz, 2 H, Fuc H-6), 1.11 (d, J = 6.5 
Hz, 1 H, Fuc H-6). 
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1H NMR of N6222 
 
 
1H NMR (D2O, 500 MHz): d 5.19 (d, J = 2.6 Hz, 0.5 H, GlcNAc-1 H-1 of a isomer), 5.13 
(s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.90 (d, J = 3.5 Hz, 0.5 H, Fuc H-1 of a isomer), 
4.89 (d, J = 3.5 Hz, 0.5 H, Fuc H-1 of b isomer), 4.75-4.80 (overlap with D2O, 1 H, Manb H-1), 
4.70 (d, J = 8.0 Hz, 0.5 H, GlcNAc-1 H-1 of b isomer), 4.67 (d, J = 7.7 Hz, 1 H, GlcNAc-2 H-1), 
4.55-4.59 (m, 3 H, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal-1 H-1), 4.47 (d, 1 H, J = 7.8 Hz, 1 H, Gal-
2 H-1), 4.26 (brs, 1 H), 4.20 (brs, 1 H), 4.10-4.14 (m, 3 H), 3.46-4.00 (m, 60 H), 2.77 (dd, J = 12.4, 
4.4 Hz, 1 H, Neu5Ac H-3eq), 2.11 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.05 (s, 6 H, Ac),2.04 (s, 3 H, 
Ac), 1.81 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3ax), 1.22 (d, J = 6.0 Hz, 1.5 H, Fuc H-6), 1.21 (d, J = 
6.0 Hz, 1.5 H, Fuc H-6) 
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1H NMR of N6223 
 
 
1H NMR (D2O, 500 MHz): d 5.14 (d, J = 2.9 Hz, 0.5 H, GlcNAc-1 H-1 of a isomer), 5.10 
(s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.88 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of a isomer), 
4.87 (d, J = 3.7 Hz, 0.5 H, Fuc H-1 of b isomer), 4.75-4.85 (overlap with D2O, 1 H, Manb H-1), 
4.64-4.68 (m, 1.5 H, GlcNAc-1 H-1 of b isomer, GlcNAc-2 H-1), 4.55-4.58 (m, 2 H, GlcNAc-3 
H-1, GlcNAc-4 H-1), 4.42-4.45 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.23 (s, 1 H), 4.17 (brs, 1 H), 
4.07-4.12 (m, 2 H), 3.46-4.00 (m, 61 H), 2.65 (dd, J = 12.5, 4.7 Hz, 1 H, Neu5Ac H-3eq), 2.08 (s, 
3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 1.70 (t, J = 12.5 
Hz, 1 H, Neu5Ac H-3ax), 1.20 (d, J = 6.4 Hz, 1.5 H, Fuc H-6), 1.19 (d, J = 6.4 Hz, 1.5 H, Fuc H-
6) 
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1H NMR of N6244 
 
 
1H NMR (D2O, 500 MHz): d 5.16 (d, J = 2.9 Hz, 0.6 H, GlcNAc-1 H-1 of a isomer), 5.11 
(s, 1 H, Man2 H-1), 5.10 (d, J = 3.8 Hz, 1 H, Fuc-2 H-1), 4.89 (s, 1 H, Man3 H-1), 4.87 (d, J = 3.8 
Hz, 0.4 H, Fuc H-1 of a isomer), 4.86 (d, J = 3.8 Hz, 0.6 H, Fuc H-1 of b isomer), 4.75-4.83 
(overlap with D2O, 1 H, Manb H-1), 4.64-4.68 (m, 1.4 H, GlcNAc-1 H-1 of b isomer, GlcNAc-2 
H-1), 4.56-4.59 (m, 2 H, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.42-4.44 (m, 2 H, Gal-1 H-1, Gal-2 H-
1), 4.24 (brs, 1 H), 4.17 (d, J = 2.4 Hz, 1 H), 4.06-4.09 (m, 3 H), 3.46-4.00 (m, 64 H), 2.65 (dd, J 
= 12.3, 4.5 Hz, 1 H, Neu5Ac H-3eq), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.02 (s, 6 H, Ac), 2.01 
(s, 3 H, Ac), 1.70 (t, J = 12.3 Hz, 1 H, Neu5Ac H-3ax), 1.20 (d, J = 6.3 Hz, 1.2 H, Fuc H-6), 1.20 
(d, J = 6.3 Hz, 1.8 H, Fuc H-6), 1.15 (d, J = 6.6 Hz, 3 H, Fuc H-6). 
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3 FUT8: FROM BIOCHEMISTRY TO SYNTHESIS OF CORE-FUCOSYLATED N-
GLYCANS. 
The work presented in this chapter is based on an accepted invited review on Pure and 
Applied Chemistry. This chapter includes work by Angie D. Calderon, Lei Li and Peng G. Wang. 
3.1 Abstract 
Glycosylation is a major post-translational modification of proteins.  Modification in 
structure of N-glycans leads to many diseases.  One of such modifications is core a-1,6 
fucosylation, which is only found in eukaryotes.  For this reason, lots of research has been done 
on approaches to synthesize a1,6-core-fucosylated N-glycans both chemically and 
enzymatically, in order to have well-defined structures that can be used as probes for glycan 
analysis and identifying functions of glycan-binding proteins. This review will focus on FUT8, 
the enzyme responsible for core fucosylation in mammals and the strategies that have been 
developed for the synthesis of a1,6 core-fucosylated N-glycans so far.   
 
Keywords: FUT8, fucosyltransferases, specificity studies, core fucosylation, alpha-1,6-
fucosyltransferase.  
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3.2 Introduction 
Post-translational modifications are very important since they influence folding, stability, 
signaling, transport and life span of proteins.1, 2 One major post-translational modification is N-
glycosylation, the alteration which is usually involved in biological processes such as: cell 
adhesion, infections, immunogenicity, and tumor metastasis.3-6 N-glycans are also proven to 
influence protein biosynthesis, folding, molecular stability, solubility, and serum half-life.5, 7-9 The 
study of human glycosyltransferases (hGTs) is important to the understanding of these important 
cellular event as well as their involvement in major diseases.2, 6, 10-14 N-glycan structures in nature 
can be very complex and diverse due to the great degree of modification that takes place.  a1,6 
core-fucosylation is a major N-glycan modification in eukaryotic systems. 
This review will focus on the biochemical properties of human a1,6 fucosyltransferase 
(FUT8) and its biosynthetic applications.  FUT8 is the enzyme responsible for all a1,6 core 
fucosylation in mammals.  This enzyme catalyzes the transfer of an L-fucose residue from GDP-
b-L-fucose (GDP-Fuc) to the inner GlcNAc of asparagine linked complex glycopeptides to 
fucosylate with an a1,6-linkage (Figure 3.2.1). 15-20  
 
Figure 3.2.1 Sample reaction catalyzed by a1,6 fucosyltransferase (FUT8). 
 
FUT8 belongs to the fucosyltransferase family (EC 2.4.1.68) and it is encoded in humans 
by the FUT8 gene.  FUT8 is a type II membrane protein on the Golgi apparatus.15 Human FUT8 
has 575 aa without a consensus N-glycosylation and its localized on chromosome 14.  FUT8 is 
structurally and genetically different from other a1,2, a1,3, and a1,4 fucosyltransferases.13, 21  
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The 3D structure of human FUT8 has been solved using recombinant proteins expressed by 
baculovirus infected Sf21 cells in 2007, which revealed a similar catalytic region to that of GT-B 
glycosyltransferases.22  
Core-fucosylation modification of N-glycans is found and conserved in vertebrates and 
invertebrates such as Caenorhabditis elegans and Drosophila melanogaster.19, 23-25  In contrast to 
the mammalian FUT8, C. elegans and D. melanogaster FUT8 has one non-conserved potential 
N-glycosylation site. 19 Many groups have studied the % identity of different animal species of 
FUT8 and they are listed in Table 2.6.7.1. 
Table 2.6.7.1 % identity of FUT8 between animal species.26, 27 
Animal species Size (aa) % Identity 
H. sapiens 575 100 
M. musculus 575 96 
B. taurus 575 95 
S. scrofa 575 93 
G. gallus 232 88 
D. melanogaster 619 60 
C. elegans 541 36 
 
FUT8 has great biological significance, loss of core-fucosylation modification can lead to 
growth retardation, emphysema, Alzheimer, and even death.	20,	28		 In addition, core-fucosylation 
is related to the regulation and function of many glycoproteins. One example is the lack of N-
glycan core-fucosylation in human IgG1 leads to enhanced antibody-dependent cellular 
cytotoxicity (ADCC).23, 29-31  Core-fucosylation also regulates the functions of immunoglobulin, 
for example, in IgG B cell receptors, it is required for the antigen recognition in humoral immune 
response.32, 33 Numerous studies have shown the overexpression of FUT8 contributes to the 
development, progression, malignancy, recurrence, invasive and metastatic properties of cancer 
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cells.10, 12-14, 34 Modifications in core-fucosylation have been linked to human diseases including 
liver cancer, pancreatic cancer, lung cancer, breast cancer, etc.35, 36 Furthermore, a1,6 core 
fucosylation has great potential as a cancer biomarker as shown by a-fetoprotein, which is highly 
core-fucosylated in hepatocellular carcinoma, but not other liver diseases.12, 37-40  Other core-
fucosylated glycoproteins such as E-cadherin and CA125 were also found to be potential cancer 
biomarkers depending on their core fucosylation level.41, 42 Core a1,6-fucosylation is a major 
modification and there is strong evidence for its importance in biological events.  
3.3 FUT8 specificity studies 
Due to its importance and medical relevance many research groups have studied the 
substrate specificity for this enzyme. 17, 23, 43, 44   Some research groups have expressed soluble 
forms of C. elegans and D. melanogaster FUT8 in Pichia pastoris.  They had also showed that 
invertebrate’s FUT8 has the same biochemical function as vertebrate FUT8 and recognizes bi-
antennary N-glycans as substrates.19 
It has been widely elucidated regarding the substrate specificity of FUT8 in vivo and in 
vitro.  Human FUT8 is active in the absence of metal cations and was shown to be inhibited by 
Ni+2, Cu+2, and Zn+2.  Optimal buffers were cacodylate and Mes when compared to Tris-HCl and 
sodium phosphate buffers at pH 7.0.18   A library of 77 well defined N-glycans synthesized by 
our group composed of three types of unlabeled N-glycans structure types: oligomannose, 
complex and hybrid as well as four simple glycan structures was used to reveal details of FUT8 
substrate specificity.  The results showed that recombinant human FUT8 expressed by our group 
recognized 11 out of the 77 substrates assayed.45 Our results support the previous substrate 
specificity studies that suggest that GlcNAc at the a-3 mannose branch of the substrate is 
required for the catalytic activity of the enzyme. 16-19, 24, 43, 45-48  Human and C. elegans FUT8 
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have relax substrate preference towards the a1,6-mannose branch, since it fucosylated 
asymmetric N-glycans.45, 48, 49 Human FUT8 recognition towards asymmetric N-glycans with an 
a1,3-linked fucose to the terminal N-acetyllactosamine (LacNAc) or sialyl LacNAc structures on 
the a1,6-mannose branch is less efficient.45 N-glycan without an a1,3-mannose branch was still 
recognized by human FUT8 with a neglectable percent conversion.45  Bisecting N-glycans and 
galactosylated GlcNAc residue at a1,3-mannose branch prevent FUT8’s activity.16, 17, 45 
Reichardt’s group, determined that C. elegans FUT8 can also core fucosylated xylose containing 
bi-antennary N-glycans relevant in invertebrates and plants.50 In general, FUT8 showed to have a 
strict requirement towards the a1,3-mannose branch, and very relaxed requirement towards the 
a1,6-mannose branch.	16-19,	24,	43,	45-48		
FUT8 substrate recognition in vivo varies slightly according to findings by various 
groups.  Even though the presence of GlcNAc at the a3 mannose branch catalyzed by N-
acetylglucosaminyltransferase I (Gn-T I) is considered to be a prerequisite for core fucosylation 
by FUT8, there are traces of high mannose core fucosylated glycans in vivo.51, 52  a1,6 Core-
fucosylated high mannose structures were identified from lysosomal proteins such as rat liver 
alkaline phosphatase51, porcine cathepsin D,52 human glucuronidase,53 and bovine 
mannosidase.54  Therefore, these structures were thought to be generated by N-
acetylglucosaminidase hydrolysis of core fucosylated hybrid type N-glycans.  After various 
groups detected the presence of a1,6 core-fucosylated high mannose structures from natural 
proteins expressed in Gn-T I knockout CHO55, and HEK293S56 cell lines, the presence of a Gn-T 
I independent fucosylation pathway was confirmed.   
Wang’s group was able to demonstrate that FUT8 is the sole enzyme responsible for a1,6 
core-fucosylation in the Gn-T I independent fucosylation pathway.   They also suggested the 
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level of core-fucosylation depends on the nature of the recombinant proteins.  This was 
demonstrated by the expression of erythropoietin (EPO), GM-CSF and ectodomain of FcgIIIA 
receptor recombinant proteins in HEK293S Gn-T I-/- cell line with an a1,6 core-fucosylation 
percentage of 50%, 30%, and 3 % respectively.  They confirmed core-fucosylation was the sole 
activity of FUT8 by the expression of EPO in stable HEK293 Gn-T I-/- cell line with both 
knockdown or overexpressed FUT8.  Their results showed knockdown cell line produced pure 
Man5GlcNAc2 glycoform, compared to EPO from FUT8 overexpressing cell line, which 
produced completely core fucosylated Man5GlcNAc.57     
3.4 Traditional versus chemo-enzymatic synthesis of core fucosylated N-glycans. 
Synthesis of core-fucosylated N-glycans has been targeted from a variety of aspects.  
Since 1996 Unverzagt’s group synthesized the first a1,6 core-fucosylated N-glycan structure 
synthetically.58  They synthesized an a1,6 core-fucosylated bi-antennary octasaccharide58 and 
nonasaccharide,59  as well as an a1,6 core-fucosylation bisecting penta-antennary 
dodecasaccharide, with an azide group for the generation of glycopeptides.60  The a1,6 core-
fucose was introduced at the last step of the chemical synthesis.  For the a-fucosylation a p-
methoxybenzyl (MPM) substituted thiofucoside was used so that it could be selectively removed 
by oxidation.61  The thiofucoside was activated by Bu4NBr/CuBr2 for coupling to the desired 
oligosaccharide.58-60, 62 They were also able to optimize the synthesis of a biantennary core-
fucosylated N-glycan by using a key building block selectively functionalized trisaccharide that 
allows glycosylation in a modular way including fucosylation at any stage of the synthesis.63 
Huang’s group has also successfully synthesized an a-2,3 sialylated core-fucosylated bi-
antennary N-glycan dodecasaccharide by combining three modules/blocks in one-pot.64  
68 
 
In the more recent years’ different approaches have been developed to generate more 
complex core fucosylated N-glycan structures in more efficient ways.  As described by Yu’s 
review on thioglycosides, there are many advantages and disadvantages to using thioglycosides 
(such as thiofucoside) for the chemical synthesis of these complex glycan structures.65  Some of 
the more known advantages are: 1. activation under extremely mild conditions, 2. stability under 
wide range of conditions, and 3. easily accessible.   However, waste resulting from these 
compounds and their promoters have very unpleasant smell and are toxic.  The requirement for 
promoters also leads to the generation of many side reactions.  These major disadvantages are a 
real problem to the environment and human health, therefore not a favorable route for industrial 
applications.65 
Several groups have been able to merge chemical synthesis with enzymatic synthesis in 
order to develop more efficient synthetic ways of producing large quantities of core-fucosylated 
N-glycans.  Wang’s group was one of the pioneers in chemically synthesize an a1,6 core-
fucosylated N-linked disaccharide to test the specificity of several endo-b-N-
acetylglucosaminidases such as Endo A, Endo M, Endo D, etc.  Endoglycosidases from 
Flavobacterium meningosepticum Endo-F2 and Endo-F3 were the only ones that recognized 
Fuca1,6GlcNAc-N-Fmoc/peptide substrate. The substrate and donor were chemically 
synthesized.  The substrate was synthesized to have an a1,6-fucosylation.  Using Endo-F2 and 
Endo-F3 they were able to synthesize both sialylated and asialylated a1,6 core-fucosylated N-
glycans.  With this approach they generate a full sized CD52 glycopeptide antigen both with 
sialic acid and a1,6 core-fucose (Figure 3.4.1).66 
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Figure 3.4.1 Chemo-enzymatic synthesis of core-fucosylated glycopeptide and glycoprotein using Endo-
F3 and mutated Endo-F3 D165A to transfer biantennary and triantennary complex N-glycans.66, 67 
 
Wang’s group years later demonstrated that by mutating Endo-F3 to Endo-F3 D165A it is 
possible to transfer not only sialylated and asialylated bi-antennary N-glycans oxazolines, but 
also tri-antennary N-glycan oxazolines to form a complex tri-antennary a1,6 core-fucosylated 
glycopeptide or glycoprotein. The donor tri-antennary oxazoline was semi-synthesized by 
digestion of fetal bovine fetuin using Endo-F3 followed by purification and desialylation using 
sialidase.  Conversion into tri-antennary glycan oxazoline was done in a single step using excess 
of 2-chloro-1,3- dimethylimidazolinium chloride and triethylamine in water.  This new 
endoglycosidase based glycosynthase can transfer bi-antennary and tri-antennary complex N-
glycans to glycopeptides and glycoproteins such as Rituximab and porcine fibrinogen (Figure 
3.4.1).  Making it possible to remodel therapeutic antibody glycosylation pattern including those 
with a1,6 core-fucosylation.67  
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Reichardt, used an 18 glycan array to test the specificity of Caenorhabditis elegans a1,6 
fucosyltransferase (CeFUT8) expressed in Pichia pastoris.  The specificity of the enzyme toward 
the different glycan structure was assayed by four lectins: Lens culinaris agglutinin (LCA), 
Aleuria aurantia lectin (AAL), Pisum sativum agglutinin (PSA), Aspergillus oryzae lectin 
(AOL), and anti-horseradish peroxidase antibody (anti-HRP).  AAL was the only lectin that 
bound with good selectivity and sensitivity to all a1,6 core-fucosylated structures. CeFUT8 
recognized A8-A17 (10 out 18 substrates assayed) (Figure 3.4.2A).  After specificity assays for 
the CeFUT8 the findings were applied to synthesize two a1,6 core-fucosylated N-glycans in 
solution.  A9 and A14 were used as substrates for the synthesis of a1,6 core-fucosylated N-
glycans in solution.  The final product Compound 5 and 7 were confirmed by NMR and MS 
(Figure 3.4.2C, Figure 3.4.2D).  All the substrates applied for the specificity studies and scale 
up synthesis for core a-1,6 fucosylation were chemically synthesized. 47  
 
Figure 3.4.2 A) CeFUT8 specificity assay using structures on glycan array. B) All substrates were 
chemically synthesized with linker. C&D) Compound 5 and 7 were synthesized using CeFUT8 from A9 
and A14 respectively, in solution and the structure was confirmed by NMR and MS.47 
 
Reichardt’s group also determined that N-glycan structures containing xylose can be a1,6 
core-fucosylated by CeFUT8.  Using 3 chemically synthesized N-glycan structures containing 
xylose (G3, G5, G6), 5 glycosyltransferases (α1,6- fucosyltransferase (CeFUT8), α1,3-
fucosyltransferase (AtFucTA/CeFUT1), β1,4-galactosyltransferase (GalT), β1,4-N-acetyl-
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galactosyltransferase (GalNAcT), LeX-type α1,6-fucosyltransferase (CeFUT6)), and 1 N-acetyl-
glucosaminidase they were able to synthesize by chemo-enzymatic extension 14 a1,6 core-
fucosylated invertebrate and plant N-glycans containing xylose Figure 3.4.3.50  
 
Figure 3.4.3 Scheme of chemo-enzymatic synthesis of 14 a1,6 core fucosylated invertebrate and plant N-
glycans containing xylose.50 Reaction Conditions: a. CeFUT8, b. GalT, c. AtFucTA/CeFUT1, d. 
GalNAcT, e. CeFUT6, f. N-acetyl-glucosaminidase. 
 
Reichardt’s group also used a similar chemo-enzymatic strategy, reviewed before, to 
generate a library of 16 13C-labeled N-glycans useful as internal standards for absolute 
quantification by MALDI-TOF.  8 out of the 16 N-glycans synthesized by their group were core-
fucosylated N-glycans and only 3 were asymmetrical.  The chemically synthesized core structure 
(Compound 2) that’s partially protected and isotope labeled (Figure 3.4.4) was used for the 
extension using 3 enzymes (β-1,4-GalT, β-1,4-N-acetyl-glucosaminidase, α-2,3-SialylT) to 
generate the N-glycan library.  In order to generate the 8 core-fucosylated N-glycans Compound 
2 was deprotected by hydrogenation before a1,6 fucosylation.49 
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Figure 3.4.4 Compound 2 before deprotection of R1=Bn by hydrogenation. In red, incorporated 13C 
isotopes. Scheme of chemo-enzymatic synthesis of CF-glycans.6, 49 Reaction Conditions: a. b-1,4-GalT, b. 
10% Pd/C, H2 c. a1,6 FucT d. N-acetyl-glucosaminidase, e. a-2,3-SialylT. 
 
Our group has also contributed to the preparation of N-glycans using a chemo-enzymatic 
strategy.  72 N-glycans were chemo-enzymatically synthesized following extension starting from 
8 core chemically synthesized N-glycans to generate 62 isomers and 4 core fucosylated glycans 
using recombinant human a-1,6 fucosyltransferase (FUT8).  The core fucosylated structures 
generate (N6030, N6000, N6211, N6212) were synthesized from N030, N000, N211, and N212 
(Figure 3.4.5).  N030 and N000 were chemically synthesized as part of the core structures used 
for extension.  N211 and N212 were chemo-enzymatically synthesized.48 The a1,6 core-
fucosylated N-glycans generated were the same as previously reported by Reichardt’s group.  
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Figure 3.4.5 CF-glycans generated by Wang lab.48 
 
A complete study on the specificity of recombinant human FUT8 was done by our group 
using the 77 N-glycan library that was mentioned above.  Using the specificity of the enzyme a 
chemo-enzymatic strategy was developed for the synthesis of a panel of a1,6 core-fucosylated 
asymmetric N-glycans. The generation of 14 core-fucosylated N-glycans was achieved by 
following the scheme in Figure 3.4.6.45   
The scheme used two chemically synthesized starting N-glycans N110 and N210 as 
substrates.  For the enzymatic extension of asymmetric core-fucosylated N-glycans N110 and 
N210 had a protected GlcNAc at the a6 or a3 mannose branch, respectively.  All the core-
fucosylated N-glycans were confirmed by MALDI-MS and HPLC retention time. Core 
fucosylated isomers N6122, N6123, N6244, N6222, N6223, and N6144 were confirmed by 1H-
NMR as well.45 
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Figure 3.4.6 (A) Scheme for chemo-enzymatic synthesis of asymmetric a1,6 core-fucosylated N-glycans 
starting with N110 as a substrate. B) Scheme for chemo-enzymatic synthesis of asymmetric a1,6 core 
fucosylated N-glycans starting with N210 as a substrate.45 Reaction conditions: a. FUT8, GDP-Fuc, 
FastAP; b. b4GALT1, UDP-Gal, FastAP, Mn2+; c. 30% ammonium hydroxide : H2O (1 : 10), 6 h; d) 
PmST1m, CMP-Neu5Ac; e. Pd2,6ST, CMP-Neu5Ac; f. Hpa1,3FT, GDP-Fuc, FastAP, Mn2+. FUT8, 
human a1,6-fucosyltransferase; b4GALT1, bovine b1,4-galactosyltransferase; PmST1m, Pasteurella 
multocida a2,3-sialyltransferase 1 mutant E271F/R313Y; Pd2,6ST, Photobacterium damselae a 2,6-
sialyltransferase; Hpa1,3FT, c-terminal 66 amino acids truncated Helicobacter pylori a1,3-
fucosyltransferase; FastAP, thermo-sensitive alkaline phosphatase.  
3.5 Conclusion 
In conclusion, FUT8 the only mammalian enzyme responsible for core a1,6 fucosylation, 
has been widely studied by many research groups.  The crystal structure has been determined as 
well as its metal, buffer and pH preferences.  The substrate specificity for the enzyme was 
studied in detailed and the results suggest there is a strict requirement towards the a1,3-mannose 
branch, but very relax requirements towards the a1,6-mannose branch. Many ways to synthesize 
core a1,6 fucosylated N-glycans have been explored both chemically and enzymatically.  These 
structures are valuable as standards for glycan analysis, and glycan-binding studies. New 
approaches to chemo-enzymatically synthesize complex a1,6 core-fucosylated N-glycans have 
allowed for the rapid accessibility to well-defined structures.  Future focused arrays containing 
core-fucosylated N-glycans will allow for identifying prospective antigens for vaccine design.  
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These new chemo-enzymatic strategies will play a crucial role in the synthesis of potential 
antigenic a-1,6 fucosylated N-glycans for glycoconjugate vaccines.47   
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4  ENZYMATIC SEPARATION OF ASYMMETRIC BI- AND TRI-ANTENNARY N-
GLYCAN ISOMERS USING FUT8 AND GN-TV 
The work presented in this chapter is based on a manuscript in preparation for submission to 
Chemical Communication. This chapter includes compounds synthesized by Angie D. Calderon, 
Lei Li, NMR data by Jun Zhou and LacZ expressed by Wanyi Guan, and Zhigang Wu. 
4.1 Abstract 
Human Gn-T V substrate specificity was studied using 17 structurally-defined N-glycans 
as acceptors.  The enzyme showed a strict requirement towards the a1,6-mannose branch, and very 
relax requirement towards the a1,3-mannose branch. A strategy for the efficient enzymatic 
separation of asymmetric N-glycan isomers was developed taking advantage of the strict substrate 
specificity of recombinant human Gn-T V and previously reported recombinant human FUT8 
glycosyltransferases.     
Keywords:  FUT8, Gn-T V, glycosyltransferases, Spodoptera frugiperda (Sf9), fucosylation.  
4.2 Introduction 
Glycosylation plays an important role in nature. Asparagine-linked glycosylation (N-
glycosylation) is one of the most important post-translational modifications of eukaryotic 
proteins. N-glycans have been shown to modulate protein’s structure and function in many ways. 
N-glycan structures were found to be very important in a variety of biological processes, 
including cell adhesion, immune responses and tumor metastasis.1-3 On the other hand, N-
glycans can influence proteins folding, stability, and immunogenicity, among others.3-6  The 
natural complexity in the biosynthesis of N-glycans have led to the generation of very diverse 
and complex glycan structures.  Synthetic and chemo-enzymatic ways for the generation of well-
defined complex symmetric and asymmetric glycan structures as standards have been widely 
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studied by many groups including ours. 7-13 The generation of a large library of well-defined 
asymmetric N-glycan isomers was recently reported by our group.14  Current methods for the 
separation and characterization of N-glycan isomer structures, have been focused on the analysis 
of small quantities for analytical purposes.  Methods such as ESI-MS/MS, IMS-MS/MS, nano-
LC-MS, HILIC-UPLC, and CE-LIF-MS among others, have successfully accomplished the 
separation and characterization of complex N-glycan isomer structures.15-24  Isolation and 
separation of isomers from natural, enzymatic or synthetic sources in large scale have proven to 
be challenging with current methods and technology.  For this reason, a simple and efficient 
strategy for the separation and production of large number of asymmetric N-glycan isomers is 
highly desirable.  Human glycosyltransferases are well known for their very strict substrate 
specificities.  Their specificity can be useful in the separation of N-glycan isomers.  Previously, 
we and others reported on FUT8 strict a6-mannose branch preference.25 
Human acetylglucosaminyltransferases V (Gn-T V) is responsible for the transfer of N-
acetylglucosamine (GlcNAc) from a uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to 
the natural acceptor to generate a b1,6GlcNAc tri-antennary N-glycan structures.26 Based on 
several studies on association of L-PHA lectin it was indicated that Gn-T V and its b1,6GlcNAc 
branching on N-glycans is implicated in advance cancers, tumor progression, and poor prognosis 
of epithelial origin cancers such as breast, and gastric cancers among others.27-42 The 
overexpression of this enzyme was linked to the regulation of cell surface glycoprotein receptors 
such as EGF, TGFb, and T cell receptors among others.43-46 A small peptide sequence in Gn-T V 
also showed to stimulate angiogenesis effects.47  Gn-T V knockout mouse appeared normal at 
birth, but as adults they displayed aberrant phenotypes such as T cell hypersensitivity, and 
autoimmune sensitivity among others.  In all of the models Gn-T V deletion was traced back to 
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altered PKB and ERK signaling pathways.43, 48-51 Gn-T V is regulated by ras-raf-ets2 signaling 
pathway activated by over expression of oncogenes such as her2-neu observed in 20-30% of 
human breast cancers.52-55  From previous studies it is known that the enzyme does not recognize 
the bisected N-glycan product from Gn-T III.56-61 This enzyme has also previously shown some 
preference towards the a1,3-mannose branch terminal GlcNAc residue.26, 62-64  
In this study, recombinant human Gn-T V was overexpressed using TIPs methodology65, 
purified and its detailed substrate specificity was studied against 17 well-defined N-glycans 
(Figure 4.2.1).  A comprehensive study was necessary to confirm such susbtste specificity, and 
structurally well-defined substrate N-glycans previously synthesized by our group represent 
perfect candidates for testing.14  An efficient strategy for the enzymatic separation of asymmetric 
N-glycan isomers was developed (See Figure 4.6.6 and Figure 4.6.7). 
This strategy is useful for the generation of asymmetric bi-, tri- and tetra-antennary complex 
N-glycan isomer structures. The strategy takes advantage of Gn-T V and previously reported FUT8 
high substrate specificity.  N-linked bi- and tri-antennary core glycans were successfully isolated 
from egg yok and fetuin, respectively.66-68 Possible N-glycan isomers were generated by digestion 
of bi- and tri-antennary core glycans using commercial PNGase F, Neuraminidase and b-
galactosidase from E.coli k12 (Ec-LacZ).   
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Figure 4.2.1 Gn-T V catalyzed reaction and substrate specificity of human Gn-T V using 17 N-glycans as 
potential acceptors,(See Table 4.6.8.1 and Table 4.6.9.1 for conversion percentage towards each glycan). 
The average conversion percentage of three replicates for each acceptor was shown. 
4.3 Results and Discussion 
Large scale separation and characterization of N-glycan isomers has proven to be 
challenging in the past, thus complicating the generation of asymmetric N-glycans in large scale.  
Herein, we present a novel strategy for the generation of asymmetric N-glycans completely from 
natural sources such as fetuin and egg yolk.  FUT8 and Gn-T V substrate specificity was applied 
to the enzymatic separation of asymmetric bi-and tri-antennary N-glycans.  FUT8 substrate 
specificity was studied in detailed previously.25  Gn-T V was expressed, purified and its detailed 
substrate specificity was assayed in order to be used in the synthetic scheme.   
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4.3.1 Generation of asymmetric biantennary and triantennary N-glycans 
 
Figure 4.3.1 A. Scheme for the synthesis of possible asymmetric N-glycan isomers from SGP from 
isolated from egg yolk. B. Scheme for the synthesis of possible asymmetric N-glycan isomers from fetal 
bovine serum. N-glycan boxed in red are the identified asymmetric N-glycan generated from lacZ 
digestion.   
 
b-galactosidase (LacZ) expressed from E. coli K12 was applied for the generation of 
asymmetric N-glycan isomers from purified substrates N001 and N3001 (Figure 4.3.1).  Bi-
antennary substrate N001 and tri-antennary N3001 were isolated from the digestion of 
sialylglycopeptide (SGP) from egg yolk66 and fetuin from fetal bovine serum67-71, respectively, 
using commercially available PNGase F and Neuraminidase (See pg. 92 §4.6.3 for a more detail 
description of the isolation and digestion of N3001).  N3001 was well characterized by HPLC-
ELSD, MALDI-MS (See pg.103 §4.6.11), and 1H-NMR, 13C NMR, and multiple 2D-NMR 
experiments (HSQC, HMBC, and HSQC-TOCSY) (See pg.112 §4.6.12).  
The substrate specificity of Ec-LacZ towards the bi-antennary and tri-antennary N-
glycans has previously suggested b-galactosidase from E.coli to cleave the galactose residue at 
the a6 mannose branch slower and yielding an equimolar isomer mixture.72, 73  For this reason, 
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first we monitored the digestion reaction of N001 with LacZ every hour for 8 hours and 
overnight to determine the best time to collect the intermediate product with only 1 galactose 
(N111/N211) residue for characterization (Figure 4.6.4).  N3001 was also recognized by LacZ 
as a substrate for galactose digestion as shown by HPLC profile pre-purification. (Figure 4.6.5).  
After prolonged incubation of acceptor with LacZ, a mixture of products was generated (N3001, 
II, III, and N3000).  N3001 without 1 galactose residue (Compound II) was the major digestion 
product.  Each compound was purified and characterized by HPLC-ELSD (See pg.103 §4.6.11), 
MALDI-MS (See pg.103 §4.6.11), and Compound II by 1H-NMR (See pg.112 §4.6.12).   
4.3.2 Substrate Specificity for human Gn-T V  
Human Gn-T V was chosen for substrate specificity study and synthetic purpose. 
Expression was achieved via a Titerless Infected-cell Preservation and Scale-up (TIPS) approach65 
using a baculovirus system (see http://glycoenzymes.ccrc.uga.edu for system and construction 
details) provided by Dr. Jarvis from the University of Wyoming.  After one-step Ni-Sepharose 
Excell (GE Healthcare) affinity purification, recombinant human Gn-T V was obtained in a scale 
of 3 mg/L of cultures as shown by western-blot (Figure 4.6.1).  Substrate specificity study was 
then performed in reactions with a total volume of 10 µL containing an N-glycan acceptor (50 
µM), donor UDP-GlcNAc (10 mM), MES buffer (100 mM, pH 7.0), MgCl2 (15 mM), 0.2% Triton 
X-100, 1 mg/ml BSA, and 0.5 mg/mL of the recombinant human Gn-T V.  After 1 h of incubation 
at 37 °C, the reactions were quenched by boiling, followed by analysis using mass spectrometry 
(MS) and high performance liquid chromatography (HPLC) monitored by fluorescence detector 
(RF-10A XL, Shimadzu). (See pg. 99 §4.6.8). Bi-antennary N-glycan acceptors and tri-antennary 
N-glycans used for the specificity studies are listed in Table 4.6.8.1 and Table 4.6.7.1, 
respectively.   
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Gn-T V recognized N-glycans with an agalactosylated and unprotected GlcNAc residue on 
the a1,6-mannose branch (N000, N040, N050, and N6000), but not those either, without a GlcNAc 
residue (N020), galactosylated (N211) or with protected GlcNAc residue (N110) on the branch.  
Among these N-glycans, Gn-T V showed the highest activity towards bi-antennary complex N-
glycan structures terminated with GlcNAc at the non-reducing end of both a1,3- and a1,6-
mannose branches N000 (72.3% conversion) and slightly decreased activities towards N6000 
(61.2% conversion), N210 (45.5% conversion), and N050 (45.6% conversion) indicated that a1,6 
fucosylation, protection or removal of GlcNAc residue at the a1,3-mannose branch can be well 
tolerated.  Removal of a1,3-mannose branch N040 (24.0% conversion), galactosylation N111 
(26.4% conversion), a1,6 sialyation N113 (37.5% conversion) and a1,3 fucosylation N114 (29.7% 
conversion) will further decrease the efficiency of Gn-T V. The presence of a2,3 sialic acid N112 
(10.6% conversion) and N115 (ND), respectively is not preferred by Gn-T V.  Gn-T V product 
from Sialyl Lewis x structure N115 was only detected after overnight reaction. Gn-T V also 
recognized tri-antennary N-glycans (N3000, N3111, and N3361) completely after prolonged time 
(N3000, N3111 and N3361).  The enzyme did not recognize N3001 (See Table 4.6.9.1)  Overall, 
our substrate specificity study using a library of 17 structurally defined N-glycans confirmed that 
Gn-T V has a strict requirement towards the a1,6-mannose branch, and a very relaxed preference 
towards the a1,3-mannose branch.  
4.3.3 Enzymatic separation of N-glycan isomers  
FUT8 and Gn-T V substrate specificity was used to determine the branch preference of 
LacZ towards N001 and N3001.  FUT8 was previously reported by our group and others to have 
a strict requirement towards b1,2-GlcNAc on the a1,3-mannose branch, but very relax towards 
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the a1,6-mannose branch.25 Here, we reported Gn-T V to have a strict requirement towards b1,2 
GlcNAc on the a1,6-mannose branch, but very relax towards the a1,3-mannose branch.  
 
Figure 4.3.2 A. LacZ 3 h digestion of N001 and identification of possible isomer intermediate using 
FUT8 and Gn-T V.  Reactions were monitored by MALDI-MS. B. LacZ 3 h digestion intermediate 
incubated with FUT8 overnight.  C. LacZ 3 h digestion intermediate incubated with Gn-T V overnight. D. 
Positive control N211 substrate incubated with FUT8 overnight.   D. Negative control N111 substrate 
incubated with FUT8 overnight. 
 
After overnight incubation with FUT8 and Gn-T V of 3 h LacZ digested N001 
intermediate, only the fucosylated product was detected by MALDI-MS (Figure 4.3.2).  This 
result suggested LacZ has a preference towards the a3-mannose branch. The results needed to be 
further investigated by performing a substrate specificity assay of LacZ against isomers N111-
AA and N211-AA (See Table 4.6.7.1).  After overnight incubation with LacZ N111-AA was 
fully digested compared to N211-AA which was only 28.6% digested.  From our specificity 
assay results LacZ demonstrated to have a preference towards N111-AA compared to N211-AA. 
In order to confirm our results, 1H-NMR and HSQC experiments were performed on the purified 
LacZ digested product after 3h in order to confirm the glycosidic linkage profile of the 
intermediate product. However, structural elucidation could not be achieved without HMBC and 
HSQC-TOCSY spectra (See pg.112 §4.6.12).  Alternatively, the structure was revealed as N211 
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bearing a Gal residue at the C-6 branch by comparison with previously reported spectrum14 and 
not an isomer mixture.  From our results we can conclude, the digestion of N001 by LacZ will 
generate a mixture of N000 and N211.  The condition for the reaction can be adjusted for the 
generation of mostly the asymmetric N211 product or N000. 
 
Figure 4.3.3 Scheme of possible isomer structures without 1 and 2 galactose residues after LacZ 
digestion. 
 
Each of the purified isomer products from the LacZ digestion of N3001 (Figure 4.6.5) 
were applied as Gn-T V substrates (Table 4.6.9.1).  All of the substrates with exception of 
N3001 were GlcNAcylated by Gn-T V completely after prolonged incubation.  Separation 
strategy using FUT8 and Gn-T V was applied as before to determine the possible isomer 
structures of N3001 without 1 and 2 galactose residues.  N3001 without 1 galactose residue was 
not recognized by FUT8, but after overnight incubation with Gn-T V it was completely 
GlcNAcylated (Figure 4.3.4).  Suggesting that from the possible isomers generated after 
digestion (Figure 4.3.3) the product generated without 1 galactose residue is N3111.  N3111 was 
synthesize in a larger scale (2.0 mg) and was well characterized by HPLC-ELSD, MALDI-MS 
(See pg.103 §4.6.11), and 1H-NMR, and multiple 2D-NMR experiments (HSQC, HMBC, and 
HSQC-TOCSY) (See pg.112 §4.6.12).    
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Figure 4.3.4 A. Scheme for identification of possible isomer intermediate using FUT8 and Gn-T V.  B. 
MALDI-MS analysis of N3001 without 1 galactose residue after overnight incubation with Gn-T V.  No 
a1,6 core-fucosylated product detected after overnight incuation with FUT8. Reaction conditions: a) 
FUT8, GDP-Fuc, FastAP; b) Gn-T V, UDP-GlcNAc, Mg2+; BSA, Tritron 100-X. Red box indicates the 
isomers identified from the MALDI-MS results (See pg.103 §4.6.11).  
 
Possible isomer without 2 galactose residues was recognized by both FUT8 and Gn-T V 
after overnight incubation (Figure 4.3.5).  Suggesting that from the possible isomers generated 
after digestion (Figure 4.3.3) the product generated without 2 galactose residues is N3361.  
N3361 was confirmed by HPLC-ELSD and MALDI-MS (See pg. 103 §4.6.11),  
FUT8
β2β4
b4b4a6
a3 N36311
β4β4
β2
X
X
a6
b4b4a6
a3 N37111
β4
β4
β2
β4
β6
β2
X
X
β2
b4b4a6
a3 N3111
β4β4
β2β4
β2β4
b4b4a6
a3 N3211
β4
β2β4
β2β4
b4b4a6
a3 N3311
β4β4
β2
Gn-T	V
Gn-T	V
Gn-T	V FUT8
FUT8
N3001 -1 Galactose residue
2069.7421
0
1000
2000
3000
4000
5000
In
te
ns
. [
a.
u.
]
1000 1200 1400 1600 1800 2000 2200 2400
m/z
N37111
A.
B.
88 
 
 
Figure 4.3.5 A. Scheme for identification of possible isomer intermediate using FUT8 and Gn-T V. B. 
MALDI-MS analysis of N3001 without 2 galactose residue after overnight incubation with FUT8 
(N36361) and Gn-T V (N37111-AEAB). Reaction conditions: a) FUT8, GDP-Fuc, FastAP; b) Gn-T V, 
UDP-GlcNAc, Mg2+; BSA, Tritron 100-X. Red box indicates the isomers identified from the MALDI-MS 
results (See pg.103 §4.6.11).  
From the specificity and separation results the following symmetric (N37000 and 
N36000), and asymmetric (N37361, N37111, and N36361) core tetra-antennary and a1,6 core 
fucosylated tri-antennary structures were synthesized. N37111, N36361, N37000, N36000, and 
N37361 were confirmed by MALDI-MS and HPLC-ELSD profile (See pg. 103 §4.6.11).  
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4.4 Conclusion 
In conclusion, recombinant human Gn-T V was overexpressed, purified and its substrate 
specificity assayed against 17 well defined N-glycans. Results showed a strict requirement 
towards the a1,6-mannose branch, and a very relax requirement towards the a1,3-mannose 
branch.  Enzymatic separation of bi- and tri-antennary asymmetric N-glycan isomers was 
successful by taking advantage of the substrate specificity requirements of two well-studied 
human glycosyltransferase FUT8 and Gn-T V substrate specificity.  Large scale separation of 
asymmetric N-glycans from natural sources is highly desirable for the generation of well-defined 
asymmetric N-glycan structures valuable as standards and probes for glycomic analysis and 
elucidation of glycan-binding protein functions.  
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4.6 Experimental 
4.6.1 Materials and enzymes 
Sialylglycopeptide (SGP), was isolated from natural source egg yolk as previously 
reported66  and tri-antennary N-glycan (N3003) was isolated from natural source Fetuin67-71 from 
fetal bovine serum purchased from Sigma-Aldrich. Thermosensitive Alkaline Phosphatase 
(FastAP) was purchased from Thermo Scientific. PNGase F and neuraminidase were purchased 
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from Sigma Aldrich. b-galactosidase (LacZ) from E.coli K12, recombinant human a-1,6-
mannosyl-glycoprotein 6-b-N-acetylglucosaminyltransferase (Gn-T V), and recombinant human 
core a1,6-fucosyltransferase (FUT8)25 were expressed and purified.  Enzymes were then desalted 
against 50 mM Tris-HCl, 100 mM NaCl, and 50% glycerol, and stored at -20 °C for long term use.  
Sugar nucleotides uridine 5’-diphospho-GlcNAc (UDP-GlcNAc) and guanosine 5’-diphospho-L-
fucose (GDP-Fuc)74 were prepared as described previously. 
4.6.2 Expression and Purification 
b-galactosidase (LacZ) was expressed in E. coli using normal expression conditions: 100 
µg/mL ampicillin, 0.1 mM IPTG, 16 degree 20 hours.  For purification, 20 mM PBS, pH 7.4, 
100 mM NaCl, 10 mM imidazole for wash buffer and 500 mM imidazole for elution buffer.  
Recombinant human a-1,6-mannosyl-glycoprotein 6-b-N-acetylglucosaminyltransferase 
(Gn-T V), and recombinant human core a1,6-fucosyltransferase (FUT8) were expressed using 
Sf9 insect cells as previously described.25, 65 The baculovirus stocks for the expression of each of 
the hGTs were kindly provided by Dr. Donald Jarvis group from University of Wyoming NIH 
grant number RR005351. Enzymes were secreted into the medium, collected after 72 hours, 
followed by purification. 
The purification of the secreted protein (Gn-T V and FUT8) was done by diluting the 
medium 1:1 with equilibration buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl) and loading the 
expression medium to an ÄKTA pure fast protein liquid chromatography system (FPLC) from 
GE healthcare life sciences with a 1 mL pre-equilibrated His-Trap Excel affinity column (GE 
Healthcare)75.  The column was rinsed using wash buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 
50 mM imidazole), and eluted with 10 mL elution buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 
250 mM imidazole).  Each enzyme was desalted and concentrated using Amicon YM-30 
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ultrafiltration membrane (Millipore) against desalting buffer (50 mM Tris-HCl pH 7.5).75 After 
desalting SDS-PAGE and Western blot were performed.  SDS-PAGE was performed using a 
10% gel the protein was transferred to PVDF membrane for western blot using iBlot transfer 
machine.  The membrane was blocked using block solution (5% non-fat milk in TBS buffer pH 
7.5 containing 0.05% Tween). Primary antibody used was anti-His mouse antibody 1:1000 
dilution in block solution, and HRP-conjugated rabbit anti mouse IgG 1:1000 dilution for the 
secondary antibody.  The protein was visualized by chemoluminescence using ECL system. 
Enzyme concentration was assayed using commercially available Pierce BCA protein assay kit 
(Thermo Fisher).   
 
 
Figure 4.6.1 Western Blot for Gn-T V. 
 
 
Figure 4.6.2 SDS-PAGE for Ec-LacZ expression and purification M. Premixed Protein Marker (High) 
(44.3-200 kDa); 1. Cell lysate; 2. Supernatant; 3. Pellet; 4. Unbound protein; 5-6. Wash; 7. Elution; 8. 
Diluted elution protein. 
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4.6.3 Generation of starting materials N001 and N3001 from natural source  
 
Figure 4.6.3 A) Scheme for the generation of N001 in one pot reaction. B) Scheme for the generation of 
N3001 in one pot reaction.  
 
N001 was generated from the one pot enzymatic digestion of SGP with PNGase F and a-
neuraminidase (Figure 4.6.3). SGP was isolated from egg yolk by the method previously 
described by our group.66  N3001 was generated from the one pot enzymatic digestion of 100 mg 
Fetuin from fetal bovine serum  (Figure 4.6.3).  Digestion reactions by PNGaseF and 
Neuraminidase were performed in 50 mM NH4HC03 buffer (pH 8.0), containing 10 mM glycan 
acceptor and PNGaseF. Reactions were allowed to proceed for overnight at 37 °C until substrates 
were totally converted to intermediate product (monitored by HPLC-ELSD as described 
previously).25 The reaction was quenched by boiling. Precipitated protein was removed by 
centrifugation and Neuraminidase was added to the reaction.  Reactions were allowed to proceed 
overnight at 37 °C until substrates were totally converted to intermediate product (monitored by 
HPLC-ELSD as described previously).25 The reaction was quenched by boiling. Precipitated 
protein was removed by centrifugation.   Sample was concentrated by rotatory evaporation and 
loaded on a G25 gel filtration column for purification.  Purification was monitored using TLC 
with a solvent system of isopropanol : ammonium hydroxide : water (7:3:2). Each collected 
fraction was analyzed by HPLC-A210nm then used to purify target glycans using a semi-
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preparative amide column (130 Å, 5 µm, 10 mm × 250 mm). The running conditions were 
solvent A: 100 mM ammonium formate, pH 3.2; solvent B: acetonitrile; flow rate: 4 mL/min; 
B%: 65-50% within 25 min. Product containing fractions were then concentrated and lyophilized 
for characterization.  N3001 was collected and lyophilized. 10 mg were isolated and 
characterized by HPLC-ELSD, MALDI-MS, and 1H-NMR.   
4.6.4 Generation of asymmetric structures using LacZ 
The generation of asymmetric structures was accomplished by the digestion of N001 
(Figure 4.6.4) and N3001 (Figure 4.6.5) by LacZ.  Digestion reactions by LacZ were performed 
in 100 mM Tris-HCl buffer (pH 7.5), containing 2 mM glycan acceptor and 1 mg/mL LacZ.  A 
reaction time course was performed for N001 to determine the best time to collect the 
intermediate with 1 galactose (Figure 4.6.4).  Reaction was sample every hour for 8 hours and 1 
overnight sample.  The percent conversion for the time course was monitor by HPLC-ELSD as 
previously described. 25  Larger scale reaction (10 mg) reactions were allowed to proceed for 3 h 
for N001 and  3 days for N3001 at 37 °C until substrates were totally converted to intermediate 
product (monitored by HPLC-ELSD as described previously).25  The reactions were then 
quenched by freezing in -80 °C for 30 min, followed with concentration by lyophilization. 
HPLC-A210nm was then used to purify target glycans using a semi-preparative amide column (130 
Å, 5 µm, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate 
, pH 3.2; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65-50% within 25 min. Product 
containing fraction were then concentrated and lyophilized for characterization.  The purity of 
each glycan was confirmed by HPLC-ELSD using an analytical Waters amide column (130 Å, 5 
µm, 4.6 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate, pH 
3.2, solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min.  
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Figure 4.6.4 LacZ digestion of N001 over time, reaction monitored by HPLC-ELSD. A) N001 control. 
B) N211 control. C) N000 control. 0) Negative control no enzyme. 1)Reaction 0 min. 2) Reaction 1 h. 3) 
Reaction 2 h. 4) Reaction 3 h, 85% conversion to intermediate product. 5) Reaction 4 h. 6) Reaction 5 h. 
7) Reaction 6 h. 8) Reaction 7 h. 9) Reaction 8 h. 10) Reaction ov, 47% conversion to intermediate 
product, and 53% conversion to N000 product. 
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Figure 4.6.5 LacZ digestion of N3001 over 4 days, each intermediate product was purified and confirmed 
by MALDI-MS. I) N3001 II) Intermediate product without 1 galactose residue (N3111). III) Intermediate 
product without 2 galactose residues (N3361). IV) Completely digested product (N000). 
4.6.5 Separation of N-glycan isomers using FUT8 and Gn-T V 
The purified isomer intermediates were used as substrates for FUT8 and Gn-T V 
reactions.  The reaction condition for FUT8 was:  N-glycan substrate (5 mM), GDP-fucose  (10 
mM), MES buffer (100 mM, pH 7.0), excess FastAP), and excess FUT8 (0.5 mg/mL).  The 
reaction condition for Gn-T V was: N-glycan substrate (5 mM), UDP-GlcNAc (10 mM), MES 
buffer (100 mM, pH 7.0), MgCl2 (15 mM), 0.2% Triton X-100, BSA (1 mg/ml), and excess Gn-
T V (0.5 mg/mL).  Reactions were incubated at 37 °C overnight. The reactions were then 
quenched by boiling for 5 min.  After centrifugation (13,000 g for 10 min), the supernatant was 
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analyzed by MALDI-MS.  N001 digestion and enzymatic separation scheme is shown in Figure 
4.6.6. N3001 digestion and enzymatic separation scheme is shown in Figure 4.6.7. 
 
Figure 4.6.6 Scheme for the separation of N-glycan isomers from digestion of N001 with LacZ using 
FUT8 and Gn-T V.  
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Figure 4.6.7 Scheme for LacZ digestion of N3001 and identification of possible isomer intermediate 
using FUT8 and Gn-T V.  Reactions were monitored by MALDI-MS. A. N3001 -1 galactose residue 
possible isomers.  B.  N3001 -2 galactose residues possible isomers.  Red box indicates the isomers 
identified from the MALDI-MS results (See pg.103 §4.6.11).  
4.6.6 N-glycan labeling using 2-AA and AEAB 
2-AA was used to labeled N001, N000, N111 and N211 for LacZ specificity studies. 
AEAB was used to labeled N3001, N3000, N3111 and N3361 for Gn-T V specificity studies. 2-
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AA or AEAB reactions were performed using the following conditions: 5 mg 2-AA or AEAB 
were dissolved in 100 µL solution of DMSO/AcOH (7:3 v/v).  6 mg NaCNBH3 were dissolved 
in the previous solution.  5 ul of labeling solution was added per every 200 µg glycan sample.  
Labeling reaction was incubated in a water bath for 2 h at 65 °C.  Labeled glycans were 
precipitated with acetronitrile (10 X the reaction volume) and incubated at -20 °C for 1 h.  
Labeled glycans were centrifuged (13,000 g for 10 min), the supernatant was removed.  The 
pellet was dried in a vacufuge for 15 min.  Labeled glycan was diluted in ddH2O and analyzed by 
MALDI-MS and HPLC-RF (2-AA :RF: excitation: 360 nm, emission: 420 nm, UV: 214 nm; 
AEAB: RF: excitation: 330 nm, emission: 420 nm, UV: 330 nm).76  Sample concentration was 
determined using the peak area and comparing to 10 nmol known standard.  
4.6.7 Substrate specificity studies on b-galactosidase (LacZ) 
Substrate specificity assay of LacZ was performed against isomers N111 and N211 chemo-
enzymatically synthesized N-glycans (with 2-AA label at reducing end) as acceptors (See Table 
4.6.7.1). Reactions were performed in 10 µL total volume.  Contains N-glycan substrate (50 µM), 
Tris-HCl buffer (100 mM, pH 7.5), LacZ (1 mg/ml).  Reactions were incubated at 37 °C overnight 
in a water bath.  Samples were collected at 0, 5, 10, 15, 20, 30, 45 min, every hour for 8 h, and at 
20 h. Reaction was quenched by freezing at 80 °C for 30 min. After centrifugation (13,000 g for 
10 min), the supernatant was analyzed by HPLC using an analytical Waters XBridge BEH amide 
column (130 Å, 5 µm, 4.6 x 250 mm), detected by UV detector SPD-20A and a fluorescence 
detector RF-10Axl. UV absorption at 214 nm or fluorescence at 360nm excitation and 420nm 
emission. Gradient elution (%B: 65– 50%) was performed with Solvent A (100 mM ammonium 
formate, pH 3.2) and Solvent B (Acetonitrile). The percent yields (average of three replicated 
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reactions, see Table 4.6.7.1) were calculated as % = Product peak area/ (Product peak area + 
Substrate peak area) × 100.  
Table 4.6.7.1 Substrate specificity of LacZ. ND, Not Detected. Conversions were monitored by HPLC-
RF, average of three replicates were shown.  
  N111-AA to N000-AA N211-AA to N000-AA 
Time Conversion (%)  Conversion (%) 
0 min ND ND 
5 min   4.1 ND 
10 min  8.0 ND 
15 min 9.9 ND 
20 min  10.9 ND 
30 min 16.7 ND 
45 min 23.8 2.4 
1 hr 30.9 3.8 
2 hr 51.1 5.2 
3 hr 65.3 8.2 
4 hr 74.9 10.2 
5 hr 83.1 11.9 
6 hr 87.3 15.3 
7 hr 90.5 16.7 
8 hr 91.2 18.5 
20 hr 100.0 28.6 
4.6.8 Substrate specificity studies on Gn-T V 
 
Figure 4.6.8 Gn-T V catalyzed reaction for bi- and tri- antennary N-glycans. 
 
A detailed substrate specificity study of Gn-T V was performed using 12 chemically or 
chemo-enzymatically synthesized N-glycans (with AEAB labeled reducing end) as acceptors 
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(Table 4.6.8.1) Reactions were performed in a 96 well PCR plate, each well (10 µL total volume) 
contains one N-glycan substrate (50 µM), UDP-GlcNAc (10 mM), MES buffer (100 mM, pH 7.0), 
MgCl2 (15 mM), 0.2% Triton X-100, BSA (1 mg/ml), and Gn-T V (0.5 mg/mL).  Reactions were 
incubated at 37 °C for 1 h in an Eppendorf thermocycler (Mastercycler Pro), followed by enzyme 
inactivation at 95 °C for 5 min. A negative control was also set up using N000 as substrate without 
enzyme. After centrifugation (13,000 g for 10 min), the supernatant was analyzed by HPLC using 
an analytical Waters XBridge BEH amide column (130 Å, 5 µm, 4.6 x 250 mm), detected by UV 
detector SPD-20A and a fluorescence detector RF-10Axl. UV absorption at 330 nm or 
fluorescence at 330nm excitation and 420nm emission. Gradient elution (%B: 65– 50%) was 
performed with Solvent A (100 mM ammonium formate, pH 3.2) and Solvent B (Acetonitrile). 
The percent yields (average of three replicated reactions, see Table 4.6.8.1) were calculated as % 
= Product peak area/ (Product peak area + Substrate peak area) × 100.  
Table 4.6.8.1 Summary of specificity studies for Gn-T V. All of the substrates were AEAB labeled. * 
complete conversion after prolonged incubation. 
Glycan Substrate Conversion (%) 
N6000 61.2 ±7.5 
N000 72.3 ±7.0 
N020 ND 
N040 24.0 ±2.5 
N050 45.6 ±4.1 
N210 45.5 ±6.5 
N110 ND 
N111 26.4 ±2.2 
N112 10.6 ±2.1 
N113 37.5 ±5.2 
N114 29.7 ±5.7 
N115 ND* 
N3001 ND 
N3000 19.6 ±1.0 
N3111 13.8 ±1.4 
N3361 18.4 ±3.4 
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4.6.9 Substrate specificity studies of Gn-T V on triantennary N-glycans  
A substrate specificity study of Gn-T V was performed using 4 enzymatically synthesized 
tri-antennary N-glycans (with AEAB labeled reducing end) as acceptors (Table 4.6.9.1) Reactions 
were performed in PCR tubes (10 µL total volume) contains one N-glycan substrate (50 µM), 
UDP-GlcNAc (10 mM), MES buffer (100 mM, pH 7.0), MgCl2 (15 mM), 0.2% Triton X-100, 
BSA (1 mg/ml), and Gn-T V (0.5 mg/mL).  Reactions were incubated at 37 °C for 1 h, overnight, 
and 3 days in an Eppendorf thermocycler (Mastercycler Pro) and water bath, followed by enzyme 
inactivation at 95 °C for 5 min. A negative control was also set up using N3000 as substrate without 
enzyme. After centrifugation (13,000 g for 10 min), the supernatant was analyzed by HPLC using 
an analytical Waters XBridge BEH amide column (130 Å, 5 µm, 4.6 x 250 mm), detected by UV 
detector SPD-20A and a fluorescence detector RF-10A xl. UV absorption at 330 nm or 
fluorescence at 330nm excitation and 420nm emission. Gradient elution (%B: 65– 50%) was 
performed with Solvent A (100 mM ammonium formate, pH 3.2) and Solvent B (Acetonitrile). 
The percent yields (average of three replicated reactions, see Table 4.6.9.1) were calculated as % 
= Product peak area/ (Product peak area + Substrate peak area) × 100.  
Table 4.6.9.1 Gn-T V substrate specificity on triantennary N-glycans. ND, Not Detected. Conversions 
were monitored by HPLC-RF, average of three replicates were shown. 
Glycan Substrate Conversion 1 h (%) Conversion 3 days (%) 
N3001-AEAB ND ND 
N3000-AEAB  19.6 ±1.0 100 
N3111-AEAB  13.8 ±1.4 100 
N3361-AEAB 18.4 ±3.4 100 
4.6.10 General methods for asymmetric glycan synthesis from natural products and 
purification 
Reactions catalyzed by LacZ, FUT8 and Gn-T V were performed and monitored by HPLC and 
MALDI-MS. Digestion reactions by PNGaseF and Neuraminidase were performed as we 
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described previously. Digestion reactions by b-galactosidase (LacZ) were performed in 100 mM 
Tris-HCl buffer (pH 7.5), containing 2 mM glycan acceptor and 1 mg/mL LacZ. Reactions were 
allowed to proceed for 3 h at 37 °C until substrates were totally converted to intermediate product 
(monitored by HPLC-ELSD as described previously). The reaction condition for FUT8 was:  N-
glycan substrate (5 mM), GDP-fucose (10 mM), MES buffer (100 mM, pH 7.0), excess FastAP), 
and excess FUT8 (0.5 mg/mL).  The reaction condition for Gn-T V was: N-glycan substrate (5 
mM), UDP-GlcNAc (10 mM), MES buffer (100 mM, pH 7.0), MgCl2 (15 mM), 0.2% Triton X-
100, BSA (1 mg/ml), and excess Gn-T V (0.5 mg/mL).  Reactions were incubated at 37 °C 
overnight or until substrates were totally converted to product. The reactions were then quenched 
by boiling for 5 min.  After centrifugation (13,000 g for 10 min), the supernatant was analyzed.  
HPLC-A210nm was then used to purify target glycans using a semi-preparative amide column (130 
Å, 5 µm, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate 
(for glycans with Neu5Ac residues) or water (for glycans without Neu5Ac residues), pH 3.2; 
solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65-50% within 25 min. Products containing 
portions were then concentrated and lyophilized for characterization.  The purity of each glycan 
was confirmed by HPLC-ELSD using an analytical Waters amide column (130 Å, 5 µm, 4.6 mm 
× 250 mm). The running conditions are solvent A: 100 mM ammonium formate, pH 3.4; solvent 
B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min.  The molecular weight of each 
N-glycans was confirmed by MALDI-MS performed on UltrafleXtreme MALDI TOF/TOF Mass 
Spectrometer (Bruker). Scan range of MS1 was according to the molecular weight of N-glycans, 
and reflector mode was used for N-glycan analysis. Mass spectra were obtained in positive mode 
with the following voltage settings: ion source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 
kV). The reflector voltage was set to 20 kV. The laser was pulsed at 7 Hz and the pulsed ion 
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extraction time was set to 400 ns. The laser power was kept in the 25–40% range. Structures of 
key intermediates and asymmetric triantennary N-glycans were confirmed by 1H NMR.   
4.6.11 HPLC profiles and MS data of purified N-glycans 
N3001 (5 mg) 
   
HPLC-ELSD, TR = 11.09 min 
 
 
 
MALDI-MS, calculated: 2005.7244; found [M+Na]+: 2028.7182 
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N3111      (3.2 mg) 
    
HPLC-ELSD, TR = 10.06 min 
 
 
MALDI-MS, calculated: 1843.6715; found [M+Na]+: 1866.6682 
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N37111      (0.2 mg) 
 
HPLC-ELSD, TR = 10.86 min 
 
 
MALDI-MS, calculated: 2046.7509.; found [M+Na]+: 2069.7421 
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N3361      (0.2 mg) 
 
HPLC-ELSD, TR = 8.87 min 
 
 
MALDI-MS, calculated: 1681.6187.; found [M+Na]+: 1704.602 
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N37361      (0.1 mg) 
 
HPLC-ELSD, TR = 14.91min 
 
 
MALDI-MS, calculated: 1884.6981.; found [M+Na]+: 1907.6851 
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N36361      (0.1 mg) 
 
HPLC-ELSD, TR = 13.97 min, 65-50 % gradient 
 
 
MALDI-MS, calculated: 1827.6766.; found [M+Na]+: 1850.6662 
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N3000      (0.2 mg) 
 
HPLC-ELSD, TR = 7.65 min 
 
MALDI-MS, calculated: 1519.5659.; found [M+Na]+: 1542.5548 
 
 
 
 
 
 
β2
b4b4a6
a3
β4
β2
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 min
0
500
1000
1500
2000
2500
uV
1542.5548
0
1000
2000
3000
4000
5000
6000
In
te
ns
. [
a.
u.
]
1400 1500 1600 1700 1800 1900
m/z
110 
 
N37000 (0.1 mg)      
 
 
MALDI-MS, calculated: 1722.6453.; found [M+Na]+: 1745.6322 
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N36000  (0.1 mg)     
 
 
 
MALDI-MS, calculated: 1665.6238.; found [M+Na]+: 1688.6191 
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4.6.12 NMR spectra and data of purified asymmetric biantennary and triantennary N-glycans 
N3001 
 
To establish the linkage profile for the N3001, 1H NMR, 13C NMR, and multiple 2D-
NMR experiments were performed to enable careful structural analysis achieving signal 
assignments and observation of key correlations. Briefly, the combination of HMBC and HSQC-
TOCSY spectra displayed 5 critical three-bond C-H correlations, which revealed the structure as 
the one having 2 antennae at C-3 branch and 1 antenna at C-6 branch. 
1H NMR 
 
1H NMR (600 MHz, D2O) δ 5.09 (s, 0.6H, H-1 GlcNAc-1α), 5.01 (s, 1H, H-1 Man-4), 4.82 (s, 
1H, H-1 Man-4’), 4.66 (s, 1H, H-1 Man-3), 4.60 (d, J = 7.6 Hz, 0.4H, H-1 GlcNAc-1β), 4.53 – 
4.43 (m, 4H, H-1 GlcNAc-2, 5, 7, and 7’), 4.40 – 4.32 (m, 3H, H-1 Gal-6, 8, and 8’), 4.16 – 4.07 
(m, 2H, H-2 Man-4 and 3), 4.01 (s, 1H, H-2 Man-4’), 3.95 (d, J = 9.3 Hz, 1H), 3.92 – 3.36 (m, 
62H), 2.04 – 1.87 (m, 15H, NHAc). 
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HSQC spectrum 
 
HMBC spectrum 
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HSQC-TOCSY spectrum 
 
 
N3111  
 
1H NMR and multiple 2D-NMR experiments were performed for the structural 
elucidation to confirm the glycosidic linkage profile. Essentially, the combination of HMBC and 
HSQC-TOCSY spectra indicated the structure as the one shown in the scheme (the cleaved Gal 
situated on upper branch). 
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1H NMR 
 
1H NMR (600 MHz, H2O+D2O) δ 5.13 (s, 0.5H, H-1 GlcNAc-1α), 5.05 (s, 1H, H-1 Man-4), 4.85 
(s, 1H, H-1 Man-4’), 4.70 (s, 1H, H-1 Man-3), 4.63 (d, J = 6.6 Hz, 0.5H, H-1 GlcNAc-1β), 4.58 
– 4.45 (m, 4H, H-1 GlcNAc-2, 5, 7, and 7’), 4.44 – 4.35 (m, 2H, H-1 Gal-6 and 8), 4.15 (m, 2H, 
H-2 Man-4 and 3), 4.05 (s, 1H, H-3 Man-4), 3.99 (d, J = 8.3 Hz, 1H, H-2 Man-4’), 3.96 – 3.89 
(m, 3H, H-4 Gal-6 and 8, H-2 GlcNAc-1α), 3.89 – 3.80 (m, 8H), 3.80 – 3.29 (m, 45H), 2.08 – 
1.91 (m, 15H, NHAc). 
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HSQC spectrum 
 
HMBC spectrum 
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HSQC-TOCSY spectrum 
 
 
N211  
 
1H NMR and HSQC experiments were performed in order to confirm the glycosidic 
linkage profile. However, structural elucidation could not been achieved without HMBC and 
HSQC-TOCSY spectra. Alternatively, the structure was revealed as the one bearing a Gal 
residue at the C-6 branch by comparison with previously reported spectrum. 
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1H NMR 
 
1H NMR (600 MHz, H2O+D2O) δ 5.12 (s, 0.6H, H-1 GlcNAc-1α), 5.04 (s, 1H, H-1 Man-4), 4.86 
(s, 1H, H-1 Man-4’), 4.70 (s, 1H, H-1 Man-3), 4.63 (d, J = 7.6 Hz, 0.4H, H-1 GlcNAc-1β), 4.56 – 
4.46 (m, 3H, H-1 GlcNAc-2, 5, and 5’), 4.41 (d, J = 7.5 Hz, 1H, H-1 Gal), 4.18 (s, 1H), 4.12 (s, 
1H), 4.04 (s, 1H), 3.95 – 3.33 (m, 45H), 2.11 – 1.91 (m, 12H, NHAc). 
HSQC spectrum 
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5 CONCLUSIONS 
TIPs method successfully allowed us to express, purify and characterize five hGTs (Gn-T 
I, Gn-T II, Gn-T III Gn-T V, and FUT8) in large scale from baculovirus-infected Sf9 cells. Each 
of the enzymes was purified and their activities assayed.  All of the enzymes were active with the 
exception of Gn-T III which show very low activity.   
Human FUT8 substrate specificity was studied in detailed and the results concluded that 
there is a strict requirement towards the a1,3-mannose branch, and very relax requirements 
towards the a1,6-mannose branch.  human FUT8 can also core-fucosylated an N-glycan in vitro 
without the a1,3-mannose branch, which was not observed before. In addition, a facile chemo-
enzymatic strategy was developed and employed for the efficient synthesis of a panel of a1,6 core-
fucosylated asymmetric N-glycans.  
Human Gn-T V substrate specificity was studied in detailed and the results concluded 
that there is a strict requirement towards the a1,6-mannose branch, and very relax requirements 
towards the a1,3-mannose branch.  A novel strategy for the enzymatic separation of bi- and tri-
antennary asymmetric N-glycan isomers was successfully developed, which takes advantage of 
the substrate specificity requirements of well-studied human glycosyltransferase FUT8 and Gn-T 
V.  Large scale synthesis and separation of asymmetric N-glycans from natural sources is highly 
desirable for the generation of well-defined asymmetric N-glycan structures valuable as 
standards and probes for glycomic analysis and elucidation of glycan-binding protein functions. 
These new chemo-enzymatic strategies will play a crucial role in the synthesis of potential 
antigenic N-glycans for future glycoconjugate vaccines.  
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APPENDICES  
Appendix A Additional human glycosyltransferases expressed in Sf9 using TIPs method.  
(Gn-T I, Gn-T II, and Gn-T III)  
Appendix A.1 SDS-PAGE for Gn-T I and Gn-T II 
 
Appendix A.2 Western-Blot for Gn-T III 
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Appendix A.3 Activity Assay for Gn-T I, Gn-T II and Gn-T III 
Gn-T I Activity assay 
 
 
ESI-MS, calculated acceptor: 910.3278; found [M+H]+: 912.3664; calculated product: 
1113.4072; found [M+H]+: 1114.4460 [M+Na]+: 1137.4274. 
 
 
 
Reaction conditions: Substrate (1.0 mM), UDP-GlcNAc (4.0 mM), HEPES pH 7.0 (20 mM), 
MnCl2 (20 mM), Gn-T II (0.1 mg/ml) 
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Gn-T II Activity assay  
 
 
ESI-MS, calculated acceptor: 1113.4072; found [M+H]+: 1114.4151; calculated product: 
1316.4865; found [M+H]+: 1317.4938, [M+Na]+: 1339.4754. 
 
 
 
Reaction conditions: Substrate (1.0 mM), UDP-GlcNAc (4.0 mM), HEPES pH 7.0 (20 mM), 
MnCl2 (20 mM), Gn-T II (0.1 mg/ml). 
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Gn-T III Activity assay 
 
 
ESI-MS, calculated acceptor: 1316.4865; found [M+Na]+: 1340.419; calculated product: 
1519.5659; found [M+Na]+: 1543.219 
 
 
 
Reaction conditions: Substrate (1.0 mM), UDP-GlcNAc (5.0 mM), MES pH 6.5 (100 mM), 
MnCl2 (10 mM), Gn-T II (0.1 mg/ml) 
 
Appendix B Additional chemo-enzymatic synthesized a1,6-core-fucosylated N-glycan 
structures  
The following core-fucosylated structures were synthesized for a collaboration project 
with Dr. Linda Hsieh-Wilson from CalTech.  The project aims to develop a chemo-enzymatic 
approach to label core-fucosylated glycans using galactosyltransferase (GALT-1), which 
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transfers a labeled galactose residue to the a1,6-core fucose of N-glycans.  The synthesized CF-
glycans provided them with well-defined structures for GALT-1 substrate specificity studies.  
Appendix B.1 Scheme for chemo-enzymatic synthesis of additional complex symmetric 
core-fucosylated N-glycans.   
 
 
Appendix B.2 HPLC profiles and MS data of purified complex symmetric N-glycans   
N000 (3 mg) 
   
 
MALDI-MS, calculated: 1316.4865; found [M+Na]+: 1339.496 
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HPLC-ELSD, TR = 11.57 min 
 
 
 
MALDI-MS, calculated: 1462.5444; found [M+Na]+: 1485.5155 
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N6001 (0.5 mg) 
   
 
HPLC-ELSD, TR = 15.30 min 
 
 
 
MALDI-MS, calculated: 1786.6501; found [M+Na]+: 1809.6393 
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N6002 (0.5 mg) 
   
 
HPLC-ELSD, TR = 17.17 min 
 
 
 
ESI-MS, calculated: 2368.8409; found [M-H]-: 2367.7881, [M-2H]-2: 1183.8853 
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